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1 
TARGETING OF LONG CHAIN 
TRIACYLGLYCEROL HYDROLASE GENE 
FOR TUBERCULOSIS TREATMENT 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of U.S. Ser. No. 11/561, 
460 filed Nov. 20, 2006, now U.S. Pat. No. 7,601,357, which 
claims priority to U.S. Provisional Patent No. 60/748,284, 
filed Dec. 7, 2005, which are incorporated herein by refer-
ence. Priority is claimed under 35 USC §120. 
GOVERNMENT SUPPORT 
This invention was made through support from the NIH, 
Grant Nos. A146582 and A135272. The govermnent may 
have certain rights in this invention. 
BACKGROUND 
Tuberculosis (TB) has been a major health problem for 
most of recorded history and Mycobacterium tuberculosis 
remains one of the world's most significant pathogens. 
Responsible for millions of new cases of tuberculosis annu-
ally (see e.g. Pablo-Mendez et al., (1998) New Engl. J. Med. 
338, 1641-1649), it is the leading cause of death from a single 
infectious agent. While the incidence of the disease declined 
in parallel with advancing standards ofliving since at least the 
mid-nineteenth century, in spite of the efforts of numerous 
health organizations worldwide, the eradication of tubercu-
losis has never been achieved, nor is imminent. 
TB is acquired by the respiratory route; actively infected 
individuals spread this infection efficiently by coughing or 
sneezing "droplet nuclei" which contain viable bacilli. Over-
crowded living conditions and shared air spaces are espe-
cially conducive to the spread of TB, underlying the increase 
in instances that have been observed in the U.S. in prison 
inmates and among the homeless in larger cities. 
Medical experts estimate that about 10 million Americans 
are infected with TB bacteria, and about 10 percent of these 
people will develop active TB in their lifetime. However, TB 
2 
ti on is infected with the latent microorganism and nearly two 
million deaths occur annually (Dye, C., Scheele, S., Dolin, P., 
Pathania, V., and Raviglione M. C. (1999) JAMA. 282, 677-
686, WHO Report. (2005) WHOIHTMITB/2005). Individuals 
5 carrying a latent infection are estimated to harbor a 2-23% 
lifetime risk of reactivation (Zahrt, T. C. (2003). Microbes 
Infect. 5, 159-167). 
If an individual has TB disease, i.e., has active TB, the 
individual typically is administered a combination of several 
10 drugs. It is very important, however, that the individual con-
tinue a correct treatment regimen for the full length of the 
treatment. If the drugs are taken incorrectly, or stopped, the 
individual can suffer a relapse and will be able to infect others 
with TB. 
15 When an individual becomes sick with TB a second time, 
the TB infection may be more difficult to treat because the TB 
bacteria have become drug resistant, i.e., TB bacteria in the 
body are unaffected by some drugs used to treat TB. Multi-
drug-resistant tuberculosis (MDR TB) is a very dangerous 
20 form of tuberculosis. In particular, some TB bacteria become 
resistant to the effects of various anti-TB drugs, and these 
resistant TB bacteria then can cause TB disease. Like regular 
TB, MDR TB can be spread to others. 
To avoid drug resistance in the treatment of TB, a four-drug 
25 regimen, i.e., isoniazid, rifampin, pyrazinamide, and strepto-
mycin, is administered to TB patients. Aminoglycosides, 
such as streptomycin, are important anti-TB agents, but their 
utility is restricted by the requirement of parenteral adminis-
tration, which is inconvenient and leads to poor patient com-
30 pliance. It is theorized that poor patient compliance also can 
lead to the development of drug resistance, and it appears that 
the frequency of streptomycin resistance among anti-TB 
drugs is surpassed only by isoniazid. 
In view of the above, an urgent need exists for new anti-TB 
35 agents useful in an effective treatment regimen for both the 
active and latent TB, and that effectively treat TB caused by 
multidrug resistant (MDR) strains of bacteria. Therefore, it 
would be advantageous to provide compounds and composi-
tions for administration to an individual in the treatment of 
40 tuberculosis. 
BRIEF DESCRIPTION OF THE DRAWINGS 
is an increasing worldwide problem, especially in Africa. It is 
estimated that, worldwide, about one billion people will 
become newly infected, over 150 million people will contract 45 
active TB, and 36 million people will die between now and 
2020 unless TB control is improved. 
FIG. 1: TG utilization by M. tuberculosis wild type and 
lipY mutant cells under nutrient starvation condition. (A) 
Autoradiogram and (B) dichromate/sulfuric acid charring of 
lipids showing utilization ofTG by wild type M. tuberculosis 
in PBS medium. After 12 days of hypoxic growth, cells were 
incubated with 1 µCi of 14C-oleic acid for 1 hr and the cells 
were washed with PBS prior to 6 hr incubation in same media. 
(C) Dichromate/sulfuric acid charring oflipids showing uti-
lization of triacylgycerol (TG)-accumulated during 12 days 
of hypoxic growth of M. tuberculosis (wild type) and lipY 
mutant cells at 0 hand by 6 h incubation in PBS and nutrient 
rich (7H9) media. Lipids were separated on Silica gel TLC 
using n-hexane:diethyl ether (9: 1, v/v) as developing solvent. 
In panel A, autoradiogram is shown from a typical experiment 
and the incorporation values of 14C into TG is shown as a 
percentage of the total 14C administered. In panel B and C, 
charred TLC chromatograms are shown from a typical 
experiment and the intensity of the TG band was determined 
in arbitrary units by the Alphaimager 2200 Gel Doc system. 
On top of each panel, the values are given as ±SEM of three 
independent measurements. 
The emergence of multi-drug resistant strains of Myca bac-
terium tuberculosis poses serious threats to the control ofthis 
disease due to the complex nature of second-line drug treat- 50 
ment (WHO Report. (2004) WHOIHTMITB/2004.343). 
Upon infection the bacterium goes through an initial replica-
tive phase inside the alveolar macrophages after which it 
enters a non-replicative, drug-resistant state of dormancy. 
This state of dormancy is probably induced by the environ- 55 
mental stress exerted upon the pathogen by the host's immune 
response. The bacterium is able to survive in this dormant 
state for decades until the host's immune system is weakened 
when it reactivates and causes the infectious disease (Dan-
nenberg, Jr., A. M., and Rook G. A. W. (1994) In Tuberculo- 60 
sis: Pathogenesis, Protection and Control, Bloom, B. R., 
(Ed.) American Society of Microbiology, Washington D.C.). 
The current anti-mycobacterial drugs are able to kill only the 
actively replicating mycobacteria and do not clear the latent 
bacteria from the host (Honer zu Bentrup, K., and Russell D. 65 
G. (2001) Trends Microbial. 9, 597-605). Thus latency is a 
major problem in TB control. One-third of the world popula-
FIG. 2: RT-PCR assessment of the induction of lip genes 
upon starvation (A) and estimation of the potential contribu-
tion to TG hydrolysis (B). M. tuberculosis H37Rv was incu-
US 8,039,605 B2 
3 
bated in PBS or in 7H9 medium for 6 h after TG accumulation 
by hypoxic growth for 12 days. Transcript levels of lips are 
shown as a fraction of23S rRNA transcripts (mean±SD from 
three independent experiments). The methods used for quan-
titation and experimental details are given in Experimental 5 
Procedures. In B, the potential relative contribution of each 
lip gene product to the total lipase activity was estimated by 
multiplying transcript level with the lipase activity of each 
gene product expressed in E. coli. 
FIG. 3: Generation of a lip Y deficient mutant of M. tuber- 10 
culosis. (A) Genomic organization of lipY (Rv3097c). (B) 
Schematic representation of the disruption construct for lip Y. 
A hatched region with grey flanks depicts the genome 
sequence of lip Y and its flanking regions used to make the 
disruption construct. Primer pairs A/B and CID were used to 15 
generate the 5'- and 3' flanks of the disruption construct. The 
part of the lipY gene (upward diagonal hatch) replaced with 
res-hyg-res gene cassette is shown. Primer pairs E/Hl, H2/F, 
and D-F/D-R (solid square check box) were used for PCR 
analysis of homologous recombination as described in the 20 
text. (C) PCR analysis of 5'-flank (lanes: 1-5, ll-LipY 
mutants; 6, wild type), deleted part of the gene (lanes: 7-11, 
ll-lipY mutants; 12, wild type) and 3'-flank (lanes: 13-17, 
fl-lip Y mutants; 18, wild type). (D) Southern blot hybridiza-
tion of five ll-lipY mutant clones and wild type probed with 25 
the part of the deleted sequence oflipY. WT, wild type. 
FIG. 4: SDS-PAGE analysis of the expression and purifi-
cation of LIPY. His-tagged LIPY was expressed in E. coli 
BL21 cells, solubilized from the 16,000x g pellet from cell 
lysate and purified by cobalt affinity chromatography 30 
(TALON) as described in Experimental Procedures. Protein 
samples were loaded on a 12% SDS-polyacrylamide gel 
under reducing conditions. Lane 1, Benchmark prestained 
molecular weight markers (Invitrogen); lane 2, 16,000xg 
supernatant from solubilized inclusion bodies; lane 3, flow- 35 
through fraction from TALON resin; lanes 4-5, 10 mM imi-
dazole wash; lanes 6-9, 150 mM imidazole eluted fractions. 
FIG. 5: Characterization of triolein hydrolase activity of 
purified LIPY. A) Time-course of [1 4C]triolein hydrolysis at 
pH 8.0 was determined using 8 µg of purified LIPY protein 40 
per assay. B) protein concentration dependence of TG 
hydrolysis (incubation time, 2 h) C) substrate concentration 
dependence of enzyme activity (incubation time, 2 h). D) 
Effect of pH on lipase activity. LIPY was incubated for 15 min 
at room temperature in 0.1 M citrate-phosphate buffer pH 6.0 45 
or 0.1 M potassium phosphate buffer pH 7.0 or 0.1 M Tris-
HCl pH 7.5/pH 8.0/pH 8.5/pH 9.0 or 0.1 M glycine-NaOH 
buffer pH 10.0 prior to the assay. Values are mean±SD for 
three replicates. 
FIG. 6: Effect ofE-600 (A), and PMSF (B), and tempera- 50 
ture on TG hydrolysis by LIPY. LIPY was incubated with 
indicated concentration of inhibitor for 15 min at room tem-
perature prior to assay at 3 7° C. In C, LIPY was incubated at 
indicated temperature for 15 min prior to assay. Values are 
mean±SD from three separate experiments. 55 
4 
17943077; SEQ ID NO: 70), Acinetobacter esterase (GI 
34559428; SEQ ID NO: 71)), Human HSL (GI 21328445; 
SEQ ID NO: 72), Pseudomonas Bll-1 lipase (GI 2853612; 
SEQ ID NO: 73), B. subtilis brefeldinA esterase (GI 414722; 
SEQ ID NO: 74), M. tuberculosis CDC1551 esterase (GI 
15840511; SEQ ID NO: 75), M. tuberculosis CDC1551 PE 
family protein (GI 15842668; SEQ ID NO: 76), R. solan-
acearum putative esterase/lipase (GI 17545158; SEQ ID NO: 
77), and S. aureus hypothetical protein (GI 15928114; SEQ 
ID NO: 78). Black shading indicates residues conserved in 
seven or more aligned sequences and shades of gray are used 
to indicate residues conserved in a few sequences. T, amino 
acids belonging to the catalytic triad. The ClustalW program 
was accessed from the European Bioinformatics Institute 
website at ebi.ac.uk/clustal. 
DETAILED DESCRIPTION 
The ability of Mycobacterium tuberculosis to go into a 
latent/dormant state and survive under such conditions for 
decades make TB control extremely difficult. Developing 
drugs targeted at the ability of the pathogen to survive under 
such latent conditions for long periods is one way to fight 
against latent TB. The invention is based, in part, on the 
inventors discovery of a novel TB gene (Rv3097 c) encoding 
an enzyme required for Mycobacterium tuberculosis to pro-
cess energy in order to enter, survive, or exit the dormancy (or 
latent) period. The gene sequence is provided as SEQ ID NO: 
1. The inventors believe that triacylglycerol (TG) could be 
used as an energy source by M. tuberculosis during the dor-
mancy period, thus its synthesis or its metabolism could be an 
ideal drug target against latent TB. 
Accordingly, the inventors have screened putative lipase/ 
esterase gene products from M. tuberculosis for long-chain 
TG hydrolase activity and have discovered that the Rv3097c 
gene product, is active as a true lipase. LIPY (PE-PGRS63), 
which is a member of PE-PGRS protein family, is a lipase 
belonging to the hormone-sensitive lipase (HSL) family and 
hydrolyzes long-chain TG with high specific activity. The 
inventors have also found that lip Y is upregulated to a much 
higher level than the transcripts of other lipase/esterase-like 
genes when mycobacteria that accumulated TG during an in 
vitro dormancy-like state were subjected to TG utilizing con-
ditions indicating that this lipase plays a role in the utilization 
ofTG for survival through dormancy. The inventors disclose 
herein that the ability to hydrolyze stored TG was drastically 
diminished in a lipY disrupted mutant (ll-lipY). 
Thus, one embodiment of the subject invention pertains to 
a method of screening for therapeutic agents useful in the 
treatment of Mycobacterium tuberculosis infection in a mam-
mal comprising the steps of i) contacting a test compound 
with a M. tuberculosis TG hydro lase (MTTGH) polypeptide, 
ii) detecting binding of said test compound to said MTTGH 
polypeptide. 
Another embodiment the subject invention is directed to a 
method of screening for therapeutic agents useful in the treat-
ment of Mycobacterium tuberculosis infection in a mammal 
comprising the steps of i) determining the activity of a 
MTTGH polypeptide at a certain concentration of a test com-
FIG. 7: Effect of detergents on LIPY activity. Purified 
LIPY was pre-incubated with the indicated concentrations of 
SDS (A), Triton X-100 (B) or Tween-20 (C) for 15 min at 
room temperature prior to assay. Activity relative to control is 
given as mean±SD from three replicates. 60 pound or in the absence of said test compound, ii) determin-
ing the activity of said polypeptide at a different concentra-
tion of said test compound. These and other embodiments 
will be described in further detail herein. 
FIG. 8: Structure-based alignment of the conserved 
domains of LIPY with lipases from the HSL family. The 
multiple sequence aligrnnent produced by Cn3D was used to 
align other members of the HSL family with LIPY using 
ClustalW and the output was manually adjusted for optimal 65 
aligrnnent. The sequences selected for alignment with LIPY 
(SEQ ID NO: 69) are A. fulgidus carboxylesterase (GI 
1. Screening Methods 
The invention provides assays for screening test com-
pounds which bind to or modulate the activity of an MTTGH 
polypeptide or bind to and inhibit or affect expression of an 
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MTTGH polynucleotide. A test compound preferably binds 
to an MTTGH polypeptide. More preferably, a test compound 
decreases or increases MTTGH activity by at least about 10, 
preferably about 50, more preferably about 75, 90, or 100% 
relative to the absence of the test compound. 
1.1. Test Compounds 
6 
Those skilled in the art equipped with teachings herein will 
appreciate that there are multiple conventional methods of 
detecting binding of a test compound. For example, binding 
of a test compound to a MTTGH polypeptide can be deter-
5 mined without labeling either of the interactants. A micro-
physiometer can be used to detect binding of a test compound 
with an MTTGH polypeptide. A microphysiometer (e.g., 
CYTOSENSOR™) is an analytical instrument that measures 
the rate at which a cell acidifies its environment using a 
Test compounds relate to agents that potentially have thera-
peutic activity, i.e., bind to or modulate the activity of an 
MTTGH polypeptide or bind to or affect expression of an 
MTTGH polynucleotide. Test compounds can be pharmaco-
logic agents already known in the art or can be compounds 
previously unknown to have any pharmacological activity. 
The compounds can be naturally occurring or designed in the 
laboratory. They can be isolated from microorganisms, ani-
mals, or plants, and can be produced recombinantly, or syn-
thesized by chemical methods known in the art. If desired, test 
compounds can be obtained using any of the numerous com-
binatorial library methods known in the art, including but not 
limited to, biological libraries, spatially addressable parallel 
solid phase or solution phase libraries, synthetic library meth-
ods requiring deconvolution, the "one-bead one-compound" 
library method, and synthetic library methods using affinity 
chromatography selection. The biological library approach is 
limited to polypeptide libraries, while the other four 25 
approaches are applicable to polypeptide, non-peptide oligo-
mer, or small molecule libraries of compounds. See Lam, 
Anticancer Drug Des. 12, 145, 1997. 
10 light-addressable potentiometric sensor (LAPS). Changes in 
this acidification rate can be used as an indicator of the inter-
action between a test compound and an MTTGH polypeptide 
(McConnell et al., Science 257, 19061912, 1992). 
In another alternative example, determining the ability of a 
15 test compound to bind to an MTTGH polypeptide can be 
accomplished using a technology such as real-time Bimo-
lecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, 
Anal Chem. 63, 23382345, 1991, and Szabo et al., Curr. Opin. 
Struct. Biol. 5, 699705, 1995). BIA is a technology for study-
20 ing biospecific interactions in real time, without labeling any 
of the interactants (e.g., BIAcore™). Changes in the optical 
phenomenon surface plasmon resonance (SPR) can be used 
as an indication of real-time reactions between biological 
molecules. 
In yet another aspect of the invention, an MTTGH polypep-
tide can be used as a "bait protein" in a two-hybrid assay or 
three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos 
et al., Cell 72, 223232, 1993; Madura et al., J. Biol. Chem. 
268, 1204612054, 1993; Bartel et al., BioTechniques 14, Methods for the synthesis of molecular libraries are well 
known in the art (see, for example, DeWitt et al., Proc. Natl. 
Acad. Sci. U.S.A. 90, 6909, 1993; Erb eta!. Proc. NatL.Acad. 
Sci. U.S.A. 91, 11422, 1994; Zuckermann et al., J. Med. 
Chem. 37, 2678, 1994; Cho et al., Science 261, 1303, 1993; 
Carell et al., Angew. Chem. Int. Ed. Engl. 33, 2059, 1994; 
Carell et al.,Angew. Chem. Int. Ed. Engl. 33, 2061; Gallop et 
al., J. Med. Chem. 37, 1233, 1994). 
1.2. High Throughput Screening 
Test compounds can be screened for the ability to bind to 
and inhibit MTTGH polypeptides or polynucleotides or to 
affect MTTGH activity or MTTGH gene expression using 
high throughput screening.Using high throughput screening, 
many discrete compounds can be tested in parallel so that 
large numbers of test compounds can be quickly screened. 
The most widely established techniques utilize 96-well 
microtiter plates. The wells of the microtiter plates typically 
require assay volumes that range from 50 to 500 µ!.In addi-
tion to the plates, many instruments, materials, pipettors, 
robotics, plate washers, and plate readers are commercially 
available to fit the 96-well format. Alternatively, "free format 
assays," or assays that have no physical barrier between 
samples, can be used. 
1.3. Binding Assays 
For binding assays, the test compound is preferably, but not 
necessarily, a small molecule which binds to and occupies, for 
example, the active site of the MTTGH polypeptide, such that 
normal biological activity is prevented. Examples of such 
small molecules include, but are not limited to, small peptides 
or peptide-like molecules. 
In binding assays, either the test compound or the MTTGH 
polypeptide can comprise a detectable label, such as a fluo-
rescent, radioisotopic, chemiluminescent, or enzymatic label, 
such as horseradish peroxidase, alkaline phosphatase, or 
luciferase. Detection of a test compound which is bound to 
the MTTGH polypeptide can then be accomplished, for 
example, by direct counting ofradioemmission, by scintilla-
tion counting, or by determining conversion of an appropriate 
substrate to a detectable product. 
30 920924, 1993; Iwabuchi et al., Oncogene 8, 16931696, 1993; 
and Brent W094/10300), to identify other proteins which 
bind to or interact with the MTTGH polypeptide and modu-
late its activity. 
In many screening embodiments, it may be desirable to 
35 immobilize either the MTTGH polypeptide (or polynucle-
otide) or the test compound to facilitate separation of bound 
from unbound forms of one or both of the interactants, as well 
as to accommodate automation of the assay. Thus, either the 
MTTGH polypeptide (or polynucleotide) or the test com-
40 pound can be bound to a solid support. Suitable solid supports 
include, but are not limited to, glass or plastic slides, tissue 
culture plates, microtiter wells, tubes, silicon chips, or par-
ticles such as beads (including, but not limited to, latex, 
polystyrene, or glass beads). Any method known in the art can 
45 be used to attach the MTTGH polypeptide (or polynucle-
otide) or test compound to a solid support, including use of 
covalent and non-covalent linkages, passive absorption, or 
pairs of binding moieties attached respectively to the 
polypeptide (or polynucleotide) or test compound and the 
50 solid support. Test compounds are preferably bound to the 
solid support in an array, so that the location of individual test 
compounds can be tracked. Binding of a test compound to a 
MTTGH polypeptide (or polynucleotide) can be accom-
plished in any vessel suitable for containing the reactants. 
55 Examples of such vessels include microtiter plates, test tubes, 
and microcentrifuge tubes. 
In a specific embodiment, the MTTGH polypeptide may be 
a fusion protein comprising a domain that allows the MTTGH 
polypeptide to be bound to a solid support. For example, 
60 glutathione S-transferase fusion proteins can be adsorbed 
onto glutathione sepharose beads (Sigma Chemical, St. 
Louis, Mo.) or glutathione derivatized microtiter plates, 
which are then combined with the test compound or the test 
compound and the nonadsorbed MTTGH polypeptide; the 
65 mixture is then incubated under conditions conducive to com-
plex formation (e.g., at physiological conditions for salt and 
pH). Following incubation, the beads ormicrotiterplate wells 
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are washed to remove any unbound components. Binding of 
the interactants can be determined either directly or indi-
rectly, as described above. Alternatively, the complexes can 
be dissociated from the solid support before binding is deter-
mined. 
Other techniques for immobilizing proteins or polynucle-
otides on a solid support also can be used in the screening 
assays of the invention. For example, either a MTTGH 
polypeptide (or polynucleotide) or a test compound can be 
immobilized utilizing conjugation of biotin and streptavidin. 
Biotinylated MTTGH polypeptides (or polynucleotides) or 
test compounds can be prepared from biotinNHS(Nhydrox-
ysuccinimide) using techniques well known in the art (e.g., 
biotinylation kit, Pierce Chemicals, Rockford, Ill.) and 
immobilized in the wells of streptavidin-coated 96 well plates 
(Pierce Chemical). Alternatively, antibodies which specifi-
cally bind to a MTTGH polypeptide, polynucleotide, or a test 
compound, but which do not interfere with a desired binding 
site, such as the active site of the MTTGH polypeptide, can be 
derivatized to the wells of the plate. Unbound target or protein 
can be trapped in the wells by antibody conjugation. 
8 
mRNA or polypeptide is less in the presence of the test 
compound than in its absence, the test compound is identified 
as an inhibitor of the mRNA or polypeptide expression. 
The level of MTTGH mRNA or polypeptide expression in 
the cells can be determined by methods well known in the art 
for detecting mRNA or polypeptide. Either qualitative or 
quantitative methods can be used. The presence of polypep-
tide products of an MTTGH polynucleotide can be deter-
mined, for example, using a variety of techniques known in 
1 o the art, including immunochemical methods such as radioim-
munoassay, Western blotting, and immunohistochemistry. 
Alternatively, polypeptide synthesis can be determined in 
vivo, in a cell culture, or in an in vitro translation system by 
detecting incorporation of labeled amino acids into a 
15 MTTGH polypeptide. 
Such screening can be carried out either in a cell-free assay 
system or in an intact cell. Any cell which expresses a 
MTTGH polynucleotide can be used in a cell-based assay 
system. The MTTGH polynucleotide can be naturally occur-
20 ring in the cell or can be introduced using techniques such as 
those described above. Either a primary culture or an estab-
lished cell line, such as CHO or human embryonic kidney 293 
cells, can be used. 
Methods for detecting such complexes, in addition to those 
described above for the GST-immobilized complexes, 
include immunodetection of complexes using antibodies 
which specifically bind to the MTTGH polypeptide or test 25 
compound, enzyme-linked assays which rely on detecting an 
activity of the MTTGH polypeptide, and SDS gel electro-
phoresis under non-reducing conditions. 
2. Pharmaceutical Compositions 
The invention also pertains to pharmaceutical composi-
tions comprising one or more therapeutic agents that are 
identified by screening methods that utilize MTTGH 
polypeptides and/or polynucleotides. Therapeutic agent(s) 
can be administered to a patient to achieve a therapeutic Screening for test compounds which bind to a MTTGH 
polypeptide or polynucleotide also can be carried out in an 
intact cell. Any cell which comprises a MTTGH polypeptide 
or polynucleotide can be used in a cell-based assay system. A 
MTTGH polynucleotide can be naturally occurring in the cell 
or can be introduced using techniques such as those described 
above. Binding of the test compound to a MTTGH polypep-
tide or polynucleotide is determined as described above. 
1.4. EnzymeAssays 
Test compounds can be tested for the ability to increase or 
decrease the triacylglycerol storage (TGS) activity of a 
MTTGH polypeptide. TGS activity can be measured, for 
example, by adapting techniques such as that described in 
U.S. Pat. No. 4,529,693 (see Example 2). Enzyme assays can 
be carried out after contacting either a purified MTTGH 
polypeptide, a cell membrane preparation, or an intact cell 
with a test compound. A test compound which decreases TGS 
activity of a MTTGH polypeptide by at least about 10, pref-
erably about 50, more preferably about 75, 90, or 100% is 
identified as a potential therapeutic agent for decreasing 
MTTGH activity. A test compound which increases TGS 
MTTGH polypeptide by at least about 10, preferably about 
50, more preferably about 75, 90, or 100% is identified as a 
potential therapeutic agent for increasing TGS activity. 
1.5. Gene Expression 
30 effect, i.e. useful in treatment of TB. Pharmaceutical compo-
sitions of the invention can comprise, for example, therapeu-
tic agents identified by a screening method embodiment 
described herein, which are identified by their ability to bind 
to or affect activity of MTTGH polypeptides, or bind to 
35 and/or affect expression MTTGH polynucleotides. The com-
positions can be administered alone or in combination with at 
least one other agent, such as stabilizing compound, which 
can be administered in any sterile, biocompatible pharmaceu-
tical carrier, including, but not limited to, saline, buffered 
40 saline, dextrose, and water. The compositions can be admin-
istered to a patient alone, or in combination with other agents, 
drugs or hormones. 
In addition to the active ingredients, these pharmaceutical 
compositions can contain suitable pharmaceutically accept-
45 able carriers comprising excipients and auxiliaries which 
facilitate processing of the active compounds into prepara-
tions which can be used pharmaceutically. Pharmaceutical 
compositions of the invention can be administered by any 
number of routes including, but not limited to, oral, intrave-
50 nous, intramuscular, intra-arterial, intramedullary, intrathe-
cal, intraventricular, transdermal, subcutaneous, intraperito-
neal, intranasal, parenteral, topical, sublingual, or rectal 
means. Pharmaceutical compositions for oral administration 
can be formulated using pharmaceutically acceptable carriers In another embodiment, test compounds which increase or 
decrease MTTGH gene expression are identified. An 
MTTGH polynucleotide is contacted with a test compound, 
and the expression of an RNA or polypeptide product of the 
MTTGH polynucleotide is determined. The level of expres-
sion of appropriate mRNA or polypeptide in the presence of 
the test compound is compared to the level of expression of 60 
mRNA or polypeptide in the absence of the test compound. 
The test compound can then be identified as a modulator of 
expression based on this comparison. For example, when 
expression of mRNA or polypeptide is greater in the presence 
55 well known in the art in dosages suitable for oral administra-
tion. Such carriers enable the pharmaceutical compositions to 
be formulated as tablets, pills, dragees, capsules, liquids, gels, 
syrups, slurries, suspensions, and the like, for ingestion by the 
patient. 
Further details on techniques for formulation and admin-
istration can be found in the latest edition ofREMINGTON'S 
PHARMACEUTICAL SCIENCES (Maack Publishing Co., 
Easton, Pa., which is incorporated herein by reference). After 
pharmaceutical compositions have been prepared, they can 
of the test compound than in its absence, the test compound is 
identified as a stimulator or enhancer of the mRNA or 
polypeptide expression. Alternatively, when expression of the 
65 be placed in an appropriate container and labeled for treat-
ment of an indicated condition. Such labeling would include 
amount, frequency, and method of administration. 
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This invention further pertains to the use of novel agents 
identified by the screening assays described above. Accord-
ingly, it is within the scope of this invention to use a thera-
peutic agent identified as described herein in an appropriate 
animal model. For example, an agent identified as described 
herein (for example, but not limited to., a modulating agent, 
an antisense nucleic acid molecule, a specific antibody, 
ribozyme, or a MTTGH polypeptide binding molecule) can 
be used in an animal model to determine the efficacy, toxicity, 
or side effects of treatment with such an agent. Furthermore, 10 
this invention pertains to uses of novel agents identified by the 
above described screening assays for treatments as described 
herein. 
10 
peutically effective dose refers to that amount of active ingre-
dient which attenuates or eliminates TB infection contrasted 
to TB infection or attenuation that occurs in the absence of the 
therapeutically effective dose. 
Therapeutic efficacy and toxicity, e.g., ED50 (the dose 
therapeutically effective in 50% of the population) and LD50 
(the dose lethal to 50% of the population), can be determined 
by standard pharmaceutical procedures in cell cultures or 
experimental animals. The dose ratio of toxic to therapeutic 
effects is the therapeutic index, and it can be expressed as the 
ratio, LD50/ED50 . 
The exact dosage will be determined by the practitioner, in 
light of factors related to the subject that requires treatment. 
Dosage and administration are adjusted to provide sufficient 
levels of the active ingredient or to maintain the desired effect. 
Factors which can be taken into account include the severity 
of the disease state, general health of the subject, age, weight, 
and gender of the subject, diet, time and frequency of admin-
istration, drug combination(s), reaction sensitivities, and tol-
erance/response to therapy. Long-acting pharmaceutical 
compositions can be administered every 3 to 4 days, every 
week, or once every two weeks depending on the half-life and 
clearance rate of the particular formulation. 
Normal dosage amounts can vary from 0.1 to 100,000 
micrograms, up to a total dose of about 1 g, depending upon 
the route of administration. Guidance as to particular dosages 
and methods of delivery is provided in the literature and 
generally available to practitioners in the art. Those skilled in 
the art will employ different formulations for nucleotides than 
for proteins or their inhibitors. Similarly, delivery of poly-
nucleotides or polypeptides will be specific to particular cells, 
conditions, locations, etc. 
Preferably, an therapeutic agent reduces expression of an 
Those skilled in the art will appreciate that numerous deliv-
ery mechanisms are available for delivering a therapeutic 15 
agent to an area of need. By way of example, the agent may be 
delivered using a liposome as the delivery vehicle. Preferably, 
the liposome is stable in the animal into which it has been 
administered for at least about 30 minutes, more preferably 
for at least about 1 hour, and even more preferably for at least 20 
about 24 hours. A liposome comprises a lipid composition 
that is capable of targeting a reagent, particularly a polynucle-
otide, to a particular site in an animal, such as a human. A 
liposome useful in the present invention comprises a lipid 
composition that is capable of fusing with the plasma mem- 25 
brane of the targeted cell to deliver its contents to the cell. 
Preferably, the transfection efficiency of a liposome is about 
0.5 µg of DNA per 16 nmole ofliposome delivered to about 
106 cells, more preferably about 1.0 µg of DNA per 16 nmole 
ofliposome delivered to about 106 cells, and even more pref- 30 
erably about 2.0 µg of DNA per 16 nmol of liposome deliv-
ered to about 106 cells. Preferably, a liposome is between 
about 100 and 500 nm, more preferably between about 150 
and 450 nm, and even more preferably between about 200 and 
400 nm in diameter. 35 MTTGH gene or the activity of an MTTGH polypeptide by at 
least about 10, preferably about 50, more preferably about 7 5, 
90, or 100% relative to the absence of the reagent. The effec-
tiveness of the mechanism chosen to decrease the level of 
expression of an MTTGH gene or the activity of an MTTGH 
Suitable liposomes for use in the present invention include 
those liposomes standardly used in, for example, gene deliv-
ery methods known to those of skill in the art. More preferred 
liposomes include liposomes having a polycationic lipid 
composition and/or liposomes having a cholesterol backbone 
conjugated to polyethylene glycol. Optionally, a liposome 
comprises a compound capable of targeting the liposome to a 
particular cell type, such as a cell-specific ligand exposed on 
the outer surface of the liposome. 
40 polypeptide can be assessed using methods well known in the 
art, such as hybridization of nucleotide probes to MTTGH-
specific mRNA, quantitative RT-PCR, immunologic detec-
tion of an MTTGH polypeptide, or measurement ofMTTGH 
activity. 
In any of the embodiments described above, any of the 
pharmaceutical compositions of the invention can be admin-
istered in combination with other appropriate therapeutic 
agents. Selection of the appropriate agents for use in combi-
nation therapy can be made by one of ordinary skill in the art, 
Complexing a liposome with a reagent such as an antisense 45 
oligonucleotide or ribozyme can be achieved using methods 
which are standard in the art (see, for example, U.S. Pat. No. 
5,705,151). Preferably, from about 0.1 µg to about 10 µg of 
polynucleotide is combined with about 8 nmol ofliposomes, 
more preferably from about 0.5 µg to about 5 µg of polynucle-
otides are combined with about 8 nmol liposomes, and even 
more preferably about 1.0 µg of polynucleotides is combined 
with about 8 nmol liposomes. 
50 according to conventional pharmaceutical principles. The 
combination of therapeutic agents can act synergistically to 
effect the treatment or prevention of the various disorders 
described above. Using this approach, one may be able to 
achieve therapeutic efficacy with lower dosages of each In another embodiment, antibodies can be delivered to 
specific tissues in vivo using receptor-mediated targeted 
delivery. Receptor-mediated DNA delivery techniques are 
taught in, for example, Findeis et al. Trends in Biotechnol. 11, 
202-05 (1993); Chiou et al., GENE THERAPEUTICS: 
METHODS AND APPLICATIONS OF DIRECT GENE 
TRANSFER (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol. 
Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 
542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 
3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991). 
2.1 Determination of a Therapeutically Effective Dose 
The determination of a therapeutically effective dose of 
therapeutic agents identified by a screening method herein is 
well within the capability of those skilled in the art. A thera-
55 agent, thus reducing the potential for adverse side effects. 
Any of the therapeutic methods described above can be 
applied to any subject in need of such therapy. 
3. Polypeptides 
M. tuberculosis TG storage (MTTGH) polypeptides 
60 according to the invention comprise at least 12, 15, 25, 50, 75, 
100, 125, 150, 175, 200, 225, 250 or 265 contiguous amino 
acids selected from the amino acid sequence shown in SEQ 
ID NO: 2, or a biologically active variant thereof, as defined 
below. A MTTGH polypeptide of the invention therefore can 
65 be a portion of an MTTGH protein, a full-length MTTGH 
protein, or a fusion protein comprising all or a portion of 
MTTGH protein. 
US 8,039,605 B2 
11 
3.1 Biologically Active Variants 
MTTGH polypeptide variants which are biologically 
active, i.e., confer an ability by Mycobacterium tuberculosis 
12 
also can be engineered to contain a cleavage site located 
between the MTTGH polypeptide-encoding sequence and 
the heterologous protein sequence, so that the MTTGH 
to store and/or process TG, also are considered MTTGH 
polypeptides for purposes of this application. Preferably, 5 
naturally or non-naturally occurring MTTGH polypeptide 
variants have amino acid sequences which are at least about 
55, 60, 65, or 70, preferably about 75, 80, 85, 90, 96, 96, or 
98% identical to the amino acid sequence shown in SEQ ID 
NO: 2 or a fragment thereof. Percent identity between a 10 
putative MTTGH polypeptide variant and an amino acid 
sequence of SEQ ID NO: 2 is determined using the Blast2 
aligmnent program (Blosum62, Expect 10, standard genetic 
codes). 
polypeptide can be cleaved and purified away from the het-
erologous moiety. 
Many kits for constructing fusion proteins are available 
from companies such as Promega Corporation (Madison, 
Wis.), Stratagene (La Jolla, Calif.), CLONTECH (Mountain 
View, Calif.), Santa Cruz Biotechnology (Santa Cruz, Calif.), 
MBL International Corporation (MIC; Watertown, Mass.), 
and Quantum Biotechnologies (Montreal, Canada; 1-888-
DNA-KITS). 
3.3 Obtaining Polypeptides 
MTTGH polypeptides can be obtained, for example, by 
purification of polypeptides from M. tuberculosis, expressed 
by ofMTTGH polynucleotide(s) and other appropriate meth-
ods as will be appreciated by those skilled in the art in view of 
the teachings herein. In a specific example, the inventors have 
expressed poly His-tagged enzyme in E. coli and have puri-
Variations in percent identity can be due, for example, to 15 
amino acid substitutions, insertions, or deletions. Amino acid 
substitutions are defined as one for one amino acid replace-
ments. They are conservative in nature when the substituted 
amino acid has similar structural and/or chemical properties. 
Examples of conservative replacements are substitution of a 20 
leucine with an isoleucine or valine, an aspartate with a 
glutamate, or a threonine with a serine. 
fied it. 
3.4 Protein Purification 
MTTGH polypeptides can be purified from any cell which 
Amino acid insertions or deletions are changes to or within 
an amino acid sequence. They typically fall in the range of 
about 1 to 5 amino acids. Guidance in determining which 25 
amino acid residues can be substituted, inserted, or deleted 
without abolishing biological or immunological activity of an 
MTTGH polypeptide can be found using computer programs 
well known in the art, such as DNASTAR software. Whether 
expresses the enzyme, including host cells which have been 
transfected with MTTGH enzyme expression constructs. A 
purified MTTGH enzyme polypeptide is separated from other 
compounds which normally associate with the MTTGH 
enzyme polypeptide in the cell, such as certain proteins, car-
bohydrates, or lipids, using methods well-known in the art. 
Such methods include, but are not limited to, size exclusion 
chromatography, ammonium sulfate fractionation, ion 
exchange chromatography, affinity chromatography, and pre-
an amino acid change results in a biologically active MTTGH 30 
polypeptide can readily be determined by assaying for 
MTTGH activity, as described for example, in the specific 
Examples, below. 
parative gel electrophoresis. A preparation of purified 
MTTGH polypeptides is at least 80% pure; preferably, the 
preparations are 90%, 95%, or 99% pure. Purity of the prepa-3.2 Fusion Proteins 
In some embodiments of the invention, it is useful to create 
fusion proteins. By way of example, fusion proteins are useful 
for generating antibodies against MTTGH polypeptide amino 
acid sequences and for use in various assay systems. For 
example, fusion proteins can be used to identify proteins 
which interact with portions of an MTTGH polypeptide. Pro-
tein affinity chromatography or library-based assays for pro-
tein-protein interactions, such as the yeast two-hybrid or 
phage display systems, can be used for this purpose. Such 
methods are well known in the art and also can be used as drug 
screens. 
A MTTGH polypeptide fusion protein comprises two 
polypeptide segments fused together by means of a peptide 
bond. For example, the first polypeptide segment can com-
prise at least 12, 15, 25, 50, 75, 100, 125, 150, 175, 200, 225, 
or 250 contiguous amino acids of SEQ ID NO: 2 or of a 
biologically active variant, such as those described above. 
The first polypeptide segment also can comprise full-length 
MTTGH protein. 
The second polypeptide segment can be a full-length pro-
tein or a protein fragment. Proteins commonly used in fusion 
protein construction include galactosidase, glucuronidase, 
green fluorescent protein (GFP), autofluorescent proteins, 
including blue fluorescent protein (BFP), glutathione-S-
transferase (GST), luciferase, horseradish peroxidase (HRP), 
and chloramphenicol acetyltransferase (CAT). Additionally, 
epitope tags are used in fusion protein constructions, includ-
ing histidine (His) tags, FLAG tags, influenza hemagglutinin 
(HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. 
Other fusion constructions can include maltose binding pro-
tein (MBP), S-tag, Lex a DNA binding domain (DBD) 
fusions, GAL4 DNA binding domain fusions, and herpes 
simplex virus (HSY) BPI 6 protein fusions. A fusion protein 
35 rations can be assessed by any means known in the art, such 
as SDS-polyacrylamide gel electrophoresis. 
4. Polynucleotides 
An MTTGH polynucleotide can be single- or double-
stranded and comprises a coding sequence or the complement 
40 of a coding sequence for an MTTGH polypeptide. A coding 
sequence for MTTGH polypeptide of SEQ ID NO: 2 is shown 
inSEQIDNO: 1. 
Degenerate nucleotide sequences encoding MTTGH 
polypeptides, as well as homologous nucleotide sequences 
45 which are at least about 50, 55, 60, 65, 60, preferably about 
7 5, 90, 96, or 98% identical to the nucleotide sequence shown 
in SEQ ID NO: 1 also are triaglycerol synthase-like enzyme 
polynucleotides. Percent sequence identity between the 
sequences of two polynucleotides is determined using com-
50 puter programs such as ALIGN which employ the PASTA 
algorithm, using an affine gap search with a gap open penalty 
of -12 and a gap extension penalty of -2. Complementary 
DNA (cDNA) molecules, species homologs, and variants of 
MTTGH polynucleotides which encode biologically active 
55 MTTGH polypeptides also are MTTGH polynucleotides. 
4.1 Identification of Polynucleotide Variants and Homologs 
Variants and homologs of the MTTGH polynucleotides 
described above also are MTTGH polynucleotides. Typically, 
homologous MTTGH polynucleotide sequences can be iden-
60 tified by hybridization of candidate polynucleotides to known 
MTTGH polynucleotides under stringent conditions, as is 
known in the art. For example, using the following wash 
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH 
7.0), 0.1 % SDS, room temperature twice, 30 minutes each; 
65 then 2xSSC, 0.1 % SDS, 50° C. once, 30 minutes; then 
2xSSC, room temperature twice, 10 minutes each homolo-
gous sequences can be identified which contain at most about 
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25-30% basepair mismatches. More preferably, homologous 
nucleic acid strands contain 15-25% basepair mismatches, 
even more preferably 5-15% basepair mismatches. 
Species homologs of the MTTGH polynucleotides dis-
closed herein also can be identified by making suitable probes 
or primers and screening cDNA expression libraries. It is well 
known that the Tm of a double-stranded DNA decreases by 
1-1.5° C. with every 1 % decrease in homology (Bonner et al., 
14 
Alternatively, synthetic chemistry techniques can be used 
to synthesize MTTGH polynucleotides. The degeneracy of 
the genetic code allows alternate nucleotide sequences to be 
synthesized which will encode a MTTGH polypeptide hav-
ing, for example, an amino acid sequence shown in SEQ ID 
NO: 2 or a biologically active variant thereof. 
4.3 Expression of Polynucleotides 
To express a MTTGH polynucleotide, the polynucleotide 
can be inserted into an expression vector which contains the J. Mo!. Biol. 81, 123 (1973). Variants ofMTTGH polynucle-
otides or polynucleotides of other species can therefore be 
identified by hybridizing a putative homologous MTTGH 
polynucleotide with a polynucleotide having a nucleotide 
sequence of SEQ ID NO: 1 or the complement thereof to form 
a test hybrid. The melting temperature of the test hybrid is 
compared with the melting temperature of a hybrid compris-
ing polynucleotides having perfectly complementary nucle-
otide sequences, and the number or percent ofbasepair mis-
matches within the test hybrid is calculated. 
10 necessary elements forthe transcription and translation of the 
inserted coding sequence. Methods which are well known to 
those skilled in the art can be used to construct expression 
vectors containing sequences encoding MTTGH polypep-
tides and appropriate transcriptional and translational control 
15 elements. These methods include in vitro recombinant DNA 
techniques, synthetic techniques, and in vivo genetic recom-
bination. Such techniques are described, for example, in Sam-
brook et al. (1989) and in Ausubel et al., CURRENT PRO-
TOCOLS IN MOLECULAR BIOLOGY, John Wiley & 
Sons, New York, N.Y., 1989. 
A variety of expression vector/host systems can be utilized 
to contain and express sequences encoding a MTTGH 
enzyme polypeptide. These include, but are not limited to, 
microorganisms, such as bacteria transformed with recombi-
Nucleotide sequences which hybridize to MTTGH poly-
nucleotides or their complements following stringent hybrid- 20 
ization and/or wash conditions also are MTTGH polynucle-
otides. Stringent wash conditions are well known and 
understood in the art and are disclosed, for example, in Sam-
brook et al., MOLECULAR CLONING: A LABORATORY 
MANUAL, rd ed., 1989, at pages 9.50-9.51. 
Typically, for stringent hybridization conditions a combi-
nation of temperature and salt concentration should be chosen 
that is approximately 12-20° C. below the calculated Tm Of 
the hybrid under study. The Tm of a hybrid between an 
MTTGH polynucleotide having a nucleotide sequence shown 30 
in SEQ ID NO: 1 or the complement thereof and a polynucle-
otide sequence which is at least about 50, preferably about 7 5, 
25 nant bacteriophage, plasmid, or cosmid DNA expression vec-
tors; yeast transformed with yeast expression vectors, insect 
cell systems infected with virus expression vectors (e.g., 
baculovirus ), plant cell systems transformed with virus 
expression vectors (e.g., cauliflower mosaic virus, CaMV; 
tobacco mosaic virus, TMV) or with bacterial expression 
vectors (e.g., Ti orpBR322 plasmids), or animal cell systems. 
The control elements or regulatory sequences are those 
90, 96, or 98% identical to one of those nucleotide sequences 
can be calculated, for example, using the equation of Bolton 
and McCarthy, Proc. Natl.Acad. Sci. U.S.A. 48, 1390 (1962): 35 
nontranslated regions of the vector enhancers, promoters, 5' 
and 3' untranslated regions which interact with host cellular 
proteins to carry out transcription and translation. Such ele-
ments can vary in their strength and specificity. Depending on 
Tm~Sl.5° C.-16.6(log10 [Na•])+0.41(% G+C)-
0.63(% formamide)-600/l), 
where !=the length of the hybrid in basepairs. 
Stringent wash conditions include, for example, 4xSSC at 
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC, 
0.1 % SDS at 65° C. Highly stringent wash conditions include, 
for example, 0.2xSSC at 65° C. 
4.2 Preparation of Polynucleotides 
A naturally occurring MTTGH polynucleotide can be iso-
lated free of other cellular components such as membrane 
components, proteins, and lipids. Polynucleotides can be 
made by a cell and isolated using standard nucleic acid puri-
fication techniques, or synthesized using an amplification 
technique, such as the polymerase chain reaction (PCR), or 
the vector system and host utilized, any number of suitable 
transcription and translation elements, including constitutive 
and inducible promoters, can be used. For example, when 
40 cloning in bacterial systems, inducible promoters such as the 
hybrid lacZ promoter of the BLUESCRIPT phagemid (Strat-
agene, LaJolla, Calif.) or pSPORTl plasmid (Life Technolo-
gies) and the like can be used. The baculovirus polyhedrin 
promoter can be used in insect cells. Promoters or enhancers 
45 derived from the genomes of plant cells (e.g., heat shock, 
RUBISCO, and storage protein genes) or from plant viruses 
(e.g., viral promoters or leader sequences) can be cloned into 
the vector. In mammalian cell systems, promoters from mam-
malian genes or from mammalian viruses are preferable. If it 
50 is necessary to generate a cell line that contains multiple 
copies of a nucleotide sequence encoding an MTTGH 
polypeptide, vectors based on SV 40 or EBY can be used with 
an appropriate selectable marker. 
by using an automatic synthesizer. Methods for isolating 
polynucleotides are routine and are known in the art. Any 
such technique for obtaining a polynucleotide can be used to 
obtain isolated MTTGH polynucleotides. For example, 
restriction enzymes and probes can be used to isolate poly- 55 
nucleotide fragments which comprises MTTGH nucleotide 
sequences. Isolated polynucleotides are in preparations 
which are free or at least 70, 80, or 90% free of other mol-
ecules. 
5. Host Cells 
According to certain embodiments of the subject inven-
tion, an MTTGH polynucleotide will need to be inserted into 
a host cell, for expression, processing and/or screening. A 
host cell strain can be chosen for its ability to modulate the 
expression of the inserted sequences or to process the 
expressed MTTGH polypeptide in the desired fashion. Such 
modifications of the polypeptide include, but are not limited 
MTTGH DNA molecules can be made with standard 60 
to, acetylation, carboxylation, glycosylation, phosphoryla-
tion, lipidation, and acylation. Posttranslational processing 
which cleaves a "prepro" form of the polypeptide also can be 
molecular biology techniques, using MTTGH mRNA as a 
template. MTTGH DNA molecules can thereafter be repli-
cated using molecular biology techniques known in the art 
and disclosed in manuals such as Sambrook et al. (1989). An 
amplification technique, such as PCR, can be used to obtain 
additional copies of polynucleotides of the invention. The 
inventors have successfully demonstrated this approach. 
65 used to facilitate correct insertion, folding and/or function. 
Different host cells which have specific cellular machinery 
and characteristic mechanisms for post-translational activi-
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ties (e.g., CHO, HeLa, MDCK, HEK293, and W138), are 
available from the American Type Culture Collection (ATCC; 
10801 University Boulevard, Manassas, Va. 20110-2209) and 
can be chosen to ensure the correct modification and process-
ing of the foreign protein. 
Stable expression is preferred for long-term, high yield 
production of recombinant proteins. For example, cell lines 
which stably express MTTGH polypeptides can be trans-
formed using expression vectors which can contain viral ori-
gins of replication and/or endogenous expression elements 
and a selectable marker gene on the same or on a separate 
vector. Following the introduction of the vector, cells can be 
allowed to grow for 12 days in an enriched medium before 
they are switched to a selective medium. The purpose of the 
selectable marker is to confer resistance to selection, and its 
presence allows growth and recovery of cells which success-
fully express the introduced MTTGH sequences. Resistant 
clones of stably transformed cells can be proliferated using 
tissue culture techniques appropriate to the cell type. See, for 
example, ANIMAL CELL CULTURE, R. I. Freshney, ed., 
1986. 
5.1 Detecting Expression 
A variety of protocols for detecting and measuring the 
expression of a MTTGH polypeptide, using either polyclonal 
or monoclonal antibodies specific for the polypeptide, are 
known in the art. Examples include enzyme-linked immun-
osorbent assay (ELISA), radioimmunoassay (RIA), and fluo-
rescence activated cell sorting (FACS). A two-site, mono-
clonal-based immunoassay using monoclonal antibodies 
reactive to two non-interfering epitopes on a MTTGH 
polypeptide can be used, or a competitive binding assay can 
be employed. These and other assays are described in Hamp-
ton et al., SEROLOGICAL METHODS: A LABORATORY 
MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox et 
al., J. Exp. Med. 158, 12111216, 1983). 
5 .2 Expression and Purification of Polypeptides 
16 
assays known in the art. Various immunoassays can be used to 
identify antibodies having the desired specificity. Numerous 
protocols for competitive binding or immunoradiometric 
assays are well known in the art. Such immunoassays typi-
cally involve the measurement of complex formation 
between an immunogen and an antibody which specifically 
binds to the immunogen. Antibodies useful for embodiments 
of the subject invention may be polyclonal, but are preferably 
monoclonal antibodies. 
10 7. Ribozymes 
Ribozymes may be one category oftest compounds poten-
tially useful as therapeutic agents for treatment of TB infec-
tion. Ribozymes are RNA molecules with catalytic activity. 
See, e.g., Cech, Science 236, 15321539; 1987; Cech, Ann. 
15 Rev. Biochem. 59, 543568; 1990, Cech, Curr. Opin. Struct. 
Biol. 2, 605609; 1992, Couture & Stinchcomb, Trends Genet. 
12, 510515, 1996. Ribozymes can be used to inhibit gene 
function by cleaving an RNA sequence, as is known in the art 
(e.g., Haseloff et al., U.S. Pat. No. 5,641,673). The mecha-
20 nism of ribozyme action involves sequence-specific hybrid-
ization of the ribozyme molecule to complementary target 
RNA, followed by endonucleolytic cleavage. Examples 
include engineered hanmierhead motif ribozyme molecules 
that can specifically and efficiently catalyze endonucleolytic 
25 cleavage of specific nucleotide sequences. 
Accordingly, another aspect of the invention pertains to 
using the coding sequence of a MTTGH polynucleotide to 
generate ribozymes which will specifically bind to mRNA 
transcribed from the MTTGH polynucleotide. Methods of 
30 designing and constructing ribozymes which can cleave other 
RNA molecules in trans in a highly sequence specific manner 
have been developed and described in the art (see Haseloff et 
al. Nature 334, 585591, 1988). For example, the cleavage 
activity of ribozymes can be targeted to specific RNAs by 
35 engineering a discrete "hybridization" region into the 
ribozyme. The hybridization region contains a sequence 
complementary to the target RNA and thus specifically 
hybridizes with the target (see, for example, Gerlach et al., EP 
Host cells transformed with nucleotide sequences encod-
ing MTTGH polypeptide can be cultured under conditions 
suitable for the expression and recovery of the protein from 
cell culture. The polypeptide produced by a transformed cell 40 
can be secreted or contained intracellularly depending on the 
sequence and/or the vector used. As will be understood by 
those of skill in the art, expression vectors containing poly-
nucleotides which encode MTTGH polypeptides can be 
designed to contain signal sequences which direct secretion 
321,201). 
Specific ribozyme cleavage sites within a MTTGH RNA 
target can be identified by scanning the target molecule for 
ribozyme cleavage sites which include the following 
sequences: GUA, GUU, and GUC. Once identified, short 
RNA sequences of between 15 and 20 ribonucleotides corre-
45 sponding to the region of the target RNA containing the 
cleavage site can be evaluated for secondary structural fea-
tures which may render the target inoperable. Suitability of 
candidate MTTGH RNA targets also can be evaluated by 
testing accessibility to hybridization with complementary oli-
of soluble MTTGH polypeptides through a prokaryotic or 
enkaryotic cell membrane or which direct the membrane 
insertion of membrane-bound MTTGH polypeptide. 
6. Antibodies 
Antibodies are referenced herein and various aspects of the 
subject invention utilize antibodies specific to MTTGH 
polypeptide(s ). As described above, one example of a thera-
peutic agent may pertain to an antibody. Any type of antibody 
known in the art can be generated to bind specifically to an 
epitope of an MTTGH polypeptide. "Antibody" as used 
herein includes intact immunoglobulin molecules, as well as 
fragments thereof, such as Fab, F(ab)2 , and Fv, which are 
capable of binding an epitope of an MTTGH polypeptide. 
Typically, at least 6, 8, 10, or 12 contiguous amino acids are 
required to form an epitope. However, epitopes which involve 
non-contiguous amino acids may require more, e.g., at least 
15, 25, or 50 amino acids. 
An antibody which specifically binds to an epitope of an 
MTTGH polypeptide can be used therapeutically, as men-
tioned, as well as in immunochemical assays, such as Western 
blots, ELISAs, radioimmunoassays, immunohistochemical 
assays, immunoprecipitations, or other immunochemical 
50 gonucleotides using ribonuclease protection assays. Longer 
complementary sequences can be used to increase the affinity 
of the hybridization sequence for the target. The hybridizing 
and cleavage regions of the ribozyme can be integrally related 
such that upon hybridizing to the target RNA through the 
55 complementary regions, the catalytic region of the ribozyme 
can cleave the target. 
Ribozymes can be introduced into cells as part of a DNA 
construct. Mechanical methods, such as microinjection, lipo-
some-mediated transfection, electroporation, or calcium 
60 phosphate precipitation, can be used to introduce a ribozyme-
containing DNA construct into cells in which it is desired to 
decrease MTTGH expression. Alternatively, if it is desired 
that the cells stably retain the DNA construct, the construct 
can be supplied on a plasmid and maintained as a separate 
65 element or integrated into the genome of the cells, as is known 
in the art. A ribozyme-encoding DNA construct can include 
transcriptional regulatory elements, such as a promoter ele-
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ment, an enhancer or UAS element, and a transcriptional 
terminator signal, for controlling transcription of ribozymes 
in the cells. 
18 
was visualized by dichromate/sulfuric acid charring of the 
TLC plates as described before (15). The charred TLC plate 
was also scanned for quantification of TG accumulation by 
using the Alphalmager 2200 Gel Doc system (Alphainno-
tech). 
Generation of lip Y disrupted mutant of M. tuberculosis 
H37Rv-The lipY gene was disrupted by allelic exchange 
using specialized transducing phage as described (16). The 
disruption construct of lip Y was made by sequential cloning 
As taught in Haseloff et al., U.S. Pat. No. 5,641,673, 
ribozymes can be engineered so that ribozyme expression 5 
will occur in response to factors which induce expression of a 
target gene. Ribozymes also can be engineered to provide an 
additional level of regulation, so that destruction of mRNA 
occurs only when both a ribozyme and a target gene are 
induced in the cells. 10 of a 953-bp 5'-flank (consisting of the first 38 bp oflip Y ORF 
and 915 bp sequence upstream oflipY ORF) and a 789-bp 
3'-flank (consisting of last 4 bp of lipY ORF and 785 bp 
sequence downstream of lip Y) of lip Y, on either side of res-
8. Long Chain TG Hydrolase Activity in Mycobacterium 
tuberculosis 
8.1 Materials and Methods 
hyg-res gene cassette in the cosmid pYUB854. The two 
flanks were generated by PCR amplification using M. tuber-
culosis H37Rv genomic DNA as template by introducing 
AflII and XbaI and HindII and SpeI sites on the ends of the 
5'-flanks and 3'-flanks respectively for directional cloning 
into pYUB854 (Table-2). The Pacl digested recombinant 
p YUB854 containing lip Y disruption construct was intro-
duced in phasmid phAE 15 9 and the recombinant transducing 
phage obtained after packaging was used to transduce M. 
tuberculosis. LipY disruption by allelic exchange was con-
firmed by PCR analyses using specific sets of primers and 
Southern hybridization (Table-2). Ten hygromycin resistant 
clones were screened by PCR using a set of primers (ll-F and 
ll-R) designed from the deleted part of the lip Y gene. The 
allelic exchange by double cross-over was confirmed with 
two sets of primers, each representing a outwardly directed 
Bacterial Strains and Culture Conditions-M. tuberculosis 
H37Rv (ATCC 25618) and ll-lipY mutant were grown in 15 
Middlebrook 7H9 (supplemented with 0.05% Tween 80, 10% 
oleic acid-albumin-dextrose-catalase enrichment, and 0.2% 
glycerol) and in Dubas-Tween SO-albumin medium (pre-
pared from Dubas broth base and Dubas medium albumin as 
per the manufacturer's instructions). All media were pur- 20 
chased from Difeo. E. coli DH5a and BL21 Star (DE3) 
(Invitrogen) used as host strains for cloning and expression 
experiments were grown on Luria-Bertani broth or agar and, 
when required, antibiotics were added to the culture media at 
the following concentrations: carbenicillin or kanamycin, 50 25 
µg/ml; hygromycin B, 150 µg/ml for E. coli or 7 5 µg/ml for M. 
tuberculosis. Other chemicals and antibiotics were from 
Sigma Chemical Co., Fisher Scientific and Calbiochem. 
DNA restriction and modifying enzymes were procured from 
New England Biolabs (Beverly, Mass.). 
Induction of lipase genes and TG utilization in M. tuber-
culosis strains under nutrient starvation after hypoxic 
stress-M. tuberculosis H3 7Rv and fl-lip Y mutant cells were 
grown under a hypoxic condition essentially as previously 
described to induce the accumulation ofTG inside the myco- 35 
bacterial cell (7). M. tuberculosis cells were inoculated into 
Middlebrook 7H9, grown aerobically at 37° C. in roller 
bottles to an OD600 of0.8 and were used to inoculate Dubos-
Tween-albuminmedium to an OD600 of0.015, grown up to an 
OD600 of0.06 and distributed in tubes or in single neck wolf 40 
bottles (Chemglass) with a 0.5 head space to culture volume 
ratio, sealed with rubber sleeve caps and slowly stirred on a 
magnetic stirrer for hypoxic growth up to 12 days. Harvested 
cells were divided into three sets. The first set was preserved 
30 hyg primer (Hl and H2) and a primer (primers E and F) in the 
mycobacterial genome beyond the flanking gene sequences 
used for making the homologous arms of the disruption con-
struct. 
DNA isolation and Southern blotting-Mycobacterial 
genomic DNA was isolated by the guanidine thiocyanate 
(GTC) method as described (17). DNA samples were 
digested with suitable restriction enzyme, separated by elec-
trophoresis in 1 % agarose gel, transferred to Nylon mem-
branes (Nytran Plus, Schleicher and Schnell, Keen, N.H.) and 
hybridized with [ a-32P]dCTP labeled probes. Probe labeling 
and preparation were performed using rediview [a-32P]dCTP 
and rediprime II random priming labeling kit (Amersham 
Biosciences) as per manufacturer's instructions. 
Cloning and Expression of M. tuberculosis lipase/esterase 
genes in E. coli-The 24 open-reading frames (ORFs) were 
amplified from the genomic DNA of M. tuberculosis H37Rv 
by PCR using Pfu Turbo Hotstart DNA polymerase (Strat-
agene) and cloned into pET200 D-TOPO expression vector 
(Invitrogen). The directionally cloned fragments were com-
pletely sequenced to confirm the sequence integrity of each 
expression construct. The constructs were used to transform 
competent cells of E. coli BL21 Star (DE3) (Invitrogen) and 
the proteins were expressed as N-terminal 6x His-tagged 
(SEQ ID NO: 79) fusion proteins after induction with IPTG 
in -80° C. and was used as control (0 h). The harvested cells 45 
of the second set were washed and resuspended in phosphate-
buffered saline (PBS) and incubated at 37° C. for 6 h. The 
cells of the third set were washed, resuspended in normal 
7H9-0ADC-Tween (7H9) medium instead of PBS and 
served as a nutrient supplemented control. These differen- 50 
tially treated cells were used to measure induction of lipase 
gene transcripts by semi-quantitative RT-PCR and to measure 
the utilization of stored TG. RNA isolation and semi quanti-
tative RT-PCR were performed as described before (7), using 
the primers shown in Table 1. 55 according to the manufacturer's protocols. Total cell lysates 
from induced cultures were prepared in 0.1 M Tris.RC! pH 
8.0 containing 1 mM DTE and used for screening for TG 
hydrolase activity of all lip gene products. Untransformed 
Cells from the three sets were autoclaved and total lipids 
were extracted with chloroform:methanol (2: 1; v/v) as previ-
ously described (7). The 12 days old wild typeM. tuberculosis 
hypoxic culture (10 ml) was also used for labeling with 1 µCi 
of [1 4C]oleic acid (specific activity, 55 Ci/mole; American 60 
Radiolabeled Chemicals) for 1 h and then the cells were 
washed with PBS before incubating in PBS for the next 6 h. 
Lipids were analyzed by silica gel thin-layer chromatography 
(TLC) using n-hexane:diethyl ether (9: 1; v/v), and the radio-
activity in the silica gel corresponding to the TG band was 65 
measured using a liquid scintillation counter (Packard). An 
autoradiogram of the TLC was prepared. The amount ofTG 
host cell lysate was used as control. 
Solubilization and purification of LIPY-In our attempts 
to produce soluble LIPY protein, we performed IPTG induc-
tion inE. coli BL21 Star (DE3) cells at 16° C., 24° C. and 37° 
C. for 4 hand 12 h. Inductions were also carried out without 
using IPTG in Dual Media (Zymo Research). In all cases 
virtually all the expressed protein was insoluble. To solubilize 
the insoluble protein, his-tagged LIPY was expressed in 500 
ml cultures by induction with 1 mM IPTG at 37° C. for 12 h 
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in LB broth. Total cell lysates were centrifuged at 1 O,OOOxg 
and the pellet was solubilized in a buffer containing 1 % (w/v) 
sodium lauroyl sarcosine, 2 mM sodium dodecyl sulfate 
(SDS), 25 mM triethanolamine, 1.5 mM CaCl2 , 50 mM 
sodium phosphate buffer pH 7 .0, 300 mM NaCl and 50 µg/ml 5 
aprotinin with shaking at 330 rpm at 10° C. for 1 h. The 
solution was clarified by centrifugation at 16,000xg for 20 
min at 4 ° C. and the supernatant was loaded onto a 5 ml 
bed-volume cobalt-affinity resin (TALON, BD Biosciences). 
Unbound proteins and detergents were removed by washing 10 
the resin with 10 bed-volumes of bind/wash buffer (50 mM 
sodium phosphate buffer pH 7.0, 300 mM NaCl) followed by 
characterized. We screened the M. tuberculosis genome for 
the presence of genes encoding such enzymes. The M. tuber-
culosis genome contains 21 ORFs annotated as putative 
lipase/esterase genes. We used the sequence of a putative TG 
lipase from M. tuberculosis strain Wl 7 in the NCBI database 
(U76006.1,Acc. No. NCBIAAB18414, Bifani et al)to screen 
the M. tuberculosis H37Rv genome for homologous genes. 
This approach identified three additional ORFs-Rvl 169c, 
Rv3097c and Rv1834, that we designate as lipX, lipY and 
lipZ respectively, to be consistent with the present nomencla-
ture of all the other lip genes in the M. tuberculosis genome. 
We included these three genes along with the 21 previously 
annotated 'lip' genes in our screen for genes encoding true 
Ii pases. 
Screening of M. tuberculosis lipase/esterase gene products 
for long-chain TG hydrolase activity-The 24 selected M. 
tuberculosis ORFs encoding putative lipase/esterase proteins 
were expressed in E. coli and total cell lysates were assayed 
for triolein hydrolase activity. Lipase activity above untrans-
10 bed-volumes of bind/wash buffer containing 10 mM imi-
dazole. The bound protein was eluted in 5 bed-volumes of 
bind/wash buffer containing 150 mM imidazole followed by 15 
5 bed-volumes of bind/wash buffer containing 250 mM imi-
dazole and 5 ml fractions were collected. Aliquots of fractions 
collected at each step of the solubilization and purification 
process were analyzed on 12% SDS-PAGE followed by coo-
massie staining. 20 formed control was normalized for the expression level of 
each recombinant protein in the total cell lysate. Triolein 
hydrolase activity in our standard radiometric assay at pH 8.0 
was by far the highest in the lysates of recombinant E. coli 
expressing LIPY followed by LIPK, LIPL and LIPC that 
Lipase Assays-Lipase activity was measured by the 
release of [1 4 C]oleic acid from [14C]triolein (55 mCi/mmol, 
American Radio labeled Chemicals) using a modified method 
of Belfrage and Vaughan (18). The reaction mixture con-
tained 50-100 µg protein from total cell lysates, 0.2 µCi [14C] 
triolein, 20 mM triolein, 2% gum arabic, 1 µg bovine serum 
albumin, 100 mM NaCl and 0.1 M Tris.RC! pH 8.0 in a total 
volume of 100 µ!. Triolein was emulsified in gum arabic and 
aliquoted into the reaction mixture at the indicated concen-
trations prior to the addition of enzyme. After incubation at 
37° C. for 2 h, the reaction mixture was extracted with 1 ml 
chloroform:methanol:hexane (1.25: 1.41: 1, v/v/v) following 
the addition of 200 µI 0.1 M NaHC03 , pH 10.5. The radio-
activity released into the upper aqueous phase was measured 
by liquid scintillation counting. Alternatively, the reaction 
mixture was acidified with 50 µI 6 N HCI and extracted with 
1 ml chloroform:methanol (2: 1, v/v). The lipids in the lower 
organic phase was resolved on silica TLC plates developed in 
hexane:diethyl ether:acetic acid (65:35:2, v/v/v) and the 
radioactivity corresponding to the internal oleic acid standard 
was determined by liquid scintillation counting. 
To investigate substrate specificity, sonicated emulsions of 
25 showed much lower activities followed by lysates expressing 
LIPX and LIPG that had even lower levels of activity. All 
other lip gene products showed little or no triolein hydrolase 
activity (Table 3). 
Utilization of stored TG and induction of lipase genes by 
30 starvation in M. tuberculosis cells grown under hypoxic con-
ditions-In order to test the hypothesis that lipase(s) release 
fatty acids from TG stores under nutrient-deprived conditions 
that might be encountered during dormancy, we cultured M. 
tuberculosis under hypoxic conditions for 12 days, a condi-
35 tion which was previously shown to cause TG accumulation 
(7), and subsequently incubated these cells in a starvation 
medium (PBS) to test whether the stored TG was utilized 
under such conditions. To label the stored TG, we incubated 
M. tuberculosis cells held under hypoxia for 12 days with 
40 14C-oleic acid for 1 h and then the labeled cells were incu-
bated in PBS for 6 h. After incubation, about 50% of the 
labeled TG was utilized under nutrient deprived condition 
(FIG. lA). Accumulation ofTG during hypoxia and utiliza-
tion during starvation was also clearly seen by dichromate/ 
20 mM [1 4 C]diolein or [14C]dioleoyl phosphatidylcholine or 
[ 14C]dioleoyl phosphatidylethanolamine or [14C]hexade-
cylpalmitate were used. To measure pH stability, the purified 
enzyme was pre-incubated in the appropriate buffer for 15 
min at 24 ° C. prior to the assay at 37° C. for 2 h. Temperature 
stability was measured by pre-incubating purified LIPY at the 
indicated temperature for 15 min prior to assay at 3 7° C. The 
effects of serine-directed reagents like diethyl-p-nitrophenyl 50 
phosphate (E-600), phenylmethanesulfonyl fluoride (PMSF), 
detergents like SDS, polyethylene glycol tert-octylphenyl 
ether (Triton X-100), polyethylene glycol sorbitan monolau-
rate (Tween-20) and various salts were determined by pre-
incubating the purified LIPY for 15 min at 24° C. with the 55 
indicated concentration of effector prior to the assay at 37° C. 
45 sulfuric acid charring of the silica gel-TLCs of the total lipids 
(FIG. lB). The intensity of the TG band showed about 50% 
decrease after 6 h of incubation in PBS. Cells incubated in 
nutrient rich medium, used as a control, did not utilize sig-
nificant amounts of the stored TG (FIG. lC). 
During the TG utilization conditions, the lipase genes 
involved in the release of fatty acids from TG would be 
expected to be induced. To test for this possibility, the tran-
script levels of all the 24 selected ORFs were measured by 
semi-quantitative RT-PCR analyses. The transcript level of 
each lip gene before starvation (0 h), after starvation (6 
h-PBS) and after incubation in nutrient rich medium (6 
for 2 h. 
8.2 Results 
Identification and cloning of M. tuberculosis lipase/es-
terase genes-M. tuberculosis probably uses fatty acids as a 
carbon source during its dormancy inside the host (8, 10). 
Previously, we identified 15 tgs genes in the genome of the 
pathogen several of which are induced under culture condi-
tions that lead to a dormancy-like state resulting in TG accu-
mulation within the bacterial cell (7). Utilization of stored TG 
would require a true lipase. However no mycobacterial gene 
that encodes long-chain TG hydro lase has been identified and 
h-7H9) are expressed as a fraction of the 23S rRNA transcript 
level of the same sample (FIG. 2A). Most of the lipase genes 
showed induction of transcript level during incubation for 6 h 
60 in PBS. The highest level of induction after 6 h starvation was 
seen in the transcripts oflipY, lipE, lipC, lipZ lipL and lipT. 
Since the lip gene products manifested very different degrees 
ofTG hydrolase activity, the possible relative contributions of 
the lipase genes to the hydrolysis of stored TG within the 
65 mycobacterial cell were assessed by multiplying the tran-
script level after 6 h starvation with the triolein hydrolase 
activity of each expressed gene product. Such an analysis 
US 8,039,605 B2 
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showed that LIPY had by far the greatest potential for hydro-
lyzing in vivo stores ofTG in the mycobacterium under such 
conditions (FIG. 2B). 
Disruption of lip Y in M. tuberculosis-LIPY showed the 
highest capacity to hydrolyze long chain TG among all the 5 
probable lipase gene products of M. tuberculosis cloned and 
expressed in E. coli. Moreover, when the organism was sub-
jected to a nutrient deprived state after the cells had accumu-
lated TG under hypoxia, lip Y was found to be the most highly 
induced gene. These results suggested that LIPY is most 10 
likely to be the major lipase involved in the hydrolysis of the 
stored TG. To test for this possibility, we generated a lipY 
knock-out mutant of M. tuberculosis (FIG. 3). lipY was dis-
rupted by allelic exchange using specialized transducing 15 
recombinant mycobacteriophage phAE159 (16). In the con-
structed lipY deletion allele, 1258 bp out of 1314 bp of total 
lip Y gene sequence was replaced with a hygromycin resis-
tance gene cassette (res-hyg-res) flanked by res (resolvase 
recognition sequence) sequences. Several mutants were iden- 20 
tified as tentative lip Y disrupted mutant (fl-lip Y) as an 804-bp 
sequence in the deleted lip Y-segment could not be amplified 
by PCR (FIG. 3C). Further PCR analysis of the flanking 
regions of the deleted part of the gene confirmed the deletion 
at the correct orientation by homologous recombination 25 
(FIG. 3C). A 1330-bp 5'-flank (primer pair-E+Hl) and a 
1007-bp 3'-flank (primer pair-H2+F) could be amplified 
from the selected disruptants, but, no product could be ampli-
fied from the wild type genomic DNA (FIG. 3B, C). Southern 
blot of EcoRI restricted genomic DNA of five putative fllip Y 30 
mutants when hybridized with a 804-bp probe generated from 
the deleted sequence of the gene didn't show any hybridiza-
tion where as the wild type control showed the hybridized 
band (FIG. 3D). lip Y transcript was absent in fl-lip Y mutant 35 
and the level of induction of the transcripts of the other lip 
genes was similar in the fl-lip Y and the wild type, when both 
were incubated in PBS or in 7H9 medium (data not shown) 
was confirmed by RT-PCR (data not shown). 
TG utilization by lip Y deficient mutant of M. tuberculo- 40 
sis-M. tuberculosis wild type and fl-lip Y mutant cells were 
subjected to TG utilizing condition as described above. When 
subjected to starvation by incubating in PBS, TG utilization in 
lip Y mutant was drastically decreased, compared to that in 
the wild type (FIG. lC). Also no significant TG hydrolysis 45 
could be detected when the cells were incubated in a nutrient 
rich medium (7H9) as a control. 
Purification of LIPY -Since LIPY showed the highest 
potential for hydrolyzing the TG stored inside the M. tuber-
culosis cell, we purified LIPY and characterized its activity. 50 
LIPY was expressed as a 6x his-tagged (SEQ ID NO: 79) 
fusion protein in E. coli at 16° C., 24° C. and 37° C. under 
various conditions of induction and was found to partition 
into the 16,000xg pellet after cell lysis in all cases. Therefore, 
we solubilized LIPY from this pellet using a low concentra- 55 
ti on of detergents that did not inhibit the activity of LIPY as 
determined by preliminary assays with total cell lysates con-
taining recombinant LIPY (data not shown). The clarified 
supernatant from the solubilized 16,000xg pellet contained a 
large quantity ofrecombinant LIPY (FIG. 4, lane 2) and was 60 
used to purify LIPY by cobalt-affinity chromatography. The 
6x his-tagged (SEQ ID NO: 79) LIPY protein was bound to 
the TALON resin and was eluted in the 150 mM imidazole 
elution step (FIG. 4). The recombinant LIPY migrated on 
SDS-PAGE with an apparent molecular weight that was 65 
slightly lower than the theoretically predicted value of 45 
kDa. The purified enzyme eluted from a pre-calibrated Super-
22 
ose-6 gel-filtration column just after the void volume suggest-
ing that the purified, recombinant LIPY exists as aggregates 
(data not shown). 
Biochemical characterization of the TG hydrolase activity 
of LIPY -The purified recombinant LIPY protein showed 
very high activity in our standard radiometric triolein 
hydrolysis assay. Lipase activity increased linearly with time 
and protein concentration (FIGS. SA, B). LIPY displayed 
typical Michaelis-Menten kinetics (FIG. SC) and the appar-
ent Km and V max values were calculated to be 7 .57 mM and 
653 .3 nmol/mg/min respectively from the rectilinear double-
reciprocal plot. LIPY hydrolyzed [14C]diolein at a lower rate 
(316.8±9.0 nmol/mg/min). LIPY did not show any fatty acid 
release when incubated with phosphatidylcholine, phosphati-
dyl ethanolamine or hexadecyl palmitate (data not shown). 
LIPY displayed optimal activity between pH 8.0 and pH 9.0 
(FIG. SD). The effect of inhibitors like E-600 which is an 
organophosphorous compound that irreversibly inhibits vari-
ous esterases and is known to target serine esterases/lipases 
was tested on LIPY. E-600 inhibited LIPY by 99.5% at 0.5 
µM (FIG. 6A) and PMSF at 5 mM inhibited LIPY activity by 
75% (FIG. 6B). The temperature stability ofLIPY was inves-
tigated by pre-incubation of the purified protein at the indi-
cated temperature for 15 min. The lipase activity of LIPY 
dropped off sharply when the enzyme was held at 50° C. or 
higher (FIG. 6C). LIPY was very stable in storage and 
retained nearly all of its original activity even after 60 days at 
4 ° C. and after 4 cycles of freezing at -20° C. followed by 
thawing. The effect of various detergents on LIPY was inves-
tigated. Lipase activity was stimulated slightly by SDS at 
concentrations up to 2 mM above which the activity was 
severely inhibited (FIG. 7A). Triton X-100 at 0.1% stimu-
lated the activity but higher concentrations were inhibitory 
(FIG. 7B). The inhibition by SDS was partially reversed by 
Triton X-100 and 20% of the original activity was recovered 
(data not shown). Tween-20 inhibited LIPY at all concentra-
tions from 0.1-2.0% (FIG. 7C). Many lipases require calcium 
for activity but LIPY was inhibited by CaCl2 . CoCl2 , MnCl2 , 
ZnCl2 , and MgCl2 also inhibited the activity. However NaCl, 
KC!, sodium acetate and potassium acetate enhanced the 
activity (Table 4). 
LIPY, a member of the HSL family-Thirteen of the 24 
putative lipase/esterases can be classified as Ii pases belonging 
to the HSL family (12) and LIPY was the only protein out of 
the twenty-four with a putative TG hydro lase activity as anno-
tated in the database (19). The product oflip Y would encode 
a protein with a predicted molecular weight of 45 kDa and a 
pl of 4.5. However, it showed only 9-21 % global amino acid 
identity with the other lipase/esterase-like proteins in the 
mycobacterial genome (Table 5). Pair-wise alignment of the 
amino acid sequence of LIPY with 35 representative lipases 
from all the eight reported families of bacterial lipases (20) 
indicated that LIPY shared only 12-23% global amino acid 
identity with known bacterial lipases. However, LIPY pos-
sesses the conserved active-site motifGDSAG (SEQ ID NO: 
61) characteristic of the HSL family. Since the crystal struc-
tures of the Bacillus subtilis brefeldinA esterase and the 
Archaeoglobus fulgidus carboxylesterase which belong to the 
HSL family have been elucidated (21, 22), we used the Cn3D 
Version 4.1 software from the Entrez System at NCBI to 
produce a structure-based sequence alignment ofLIPY with 
the members of the HSL family. The alignment of conserved 
domains produced by Cn3D was then used to align other 
selected members of the HSL family by Clusta!W multiple 
sequence alignment program. The multiple sequence align-
ment output from Clusta!W was then adjusted manually to 
achieve maximum similarity between the amino acid 
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21. Wei, Y., Contreras, J. A., Sheffield, P., Osterlund, T., 
Derewenda, U., Kneusel, R. E., Matern, U., Holm, C., and 
Derewenda Z. S. (1999) Nature Struct. Biol. 6, 
22. De Simone, G., Menchise, V., Manco, G., Mandrich L., 
Sorrentino N., Lang, D., Rossi, M., and Pedone C. (2001) 
J. Mal. Biol. 314, 507-518 
23. Jaeger, K-E., Dijkstra, B. W., and Reetz M. T. (1999) 
Annu. Rev. Microbial. 53, 315-351 
24. Vereecke, D., Cornelis, K., Temmerman, W., Holsters, M., 
sequences.As shown in FIG. 8, this alignment revealed a high 
degree of similarity between the C-terminal half ofLIPY and 
other members of the HSL family. This region of high simi-
larity includes the catalytic domain with the consensus pen-
tapeptide GDSAG (SEO ID NO: 61) containing the active 5 
serine residue and the strictly conserved HGGG (SEO ID NO: 
68) motif of unknown function (23) located immediately 
upstream of the active site consensus motif. The aspartate and 
histidine residues of the active-site are also conserved with 
the other members of the HSL family. 10 and Goethals K. (2002) Trends Microbial. 10, 485-488 
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TABLE 1 
Primers used for RT-PCR analyses of transcripts 
of lipase genes induced in M. tuberculosis 
Gene Primer pairs ( 5' -3') 
lipC (Rv0220) F, GGTAAGCACCTCAAGCCGCTCGGC 
R, GCGCTGAACCACTACCCGCTCCAG 
lipD (Rv1923) F, GGTGTTCAGCGGGCGAGCGAGTTC 
R, GGCGCAACCACCGTCACTCCTCAC 
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TABLE 1-continued 
Primers used for RT-PCR analyses of transcripts 
of lipase genes induced in M. tuberculosis 
Gene 
lipE (Rv3775) 
lipF (Rv3487c) 
lipG (Rv0646c) 
lipH (Rv1399c) 
lip I (Rv1400c) 
lipJ (Rv1900c) 
lipK (Rv2385) 
lipL (Rv1497) 
lipM (Rv2284) 
lipN (Rv2970c) 
lipO (Rv1426c) 
lipP (Rv2463) 
lipQ (Rv2485c) 
lipR (Rv3084) 
lips (Rv31 76c) 
lipT (Rv2045c) 
lipU (Rv1076) 
lipV (Rv3203) 
lipW (Rv0217c) 
lipX (Rv1169c) 
lipY (Rv3097c) 
lipZ (Rv1834) 
Primer pairs (5'-3') 
p, CTAGACGCCGTCACGGCAACCGGC 
R, ACTGGGCGCGACCAGCGGCACATC 
p, CGACGGCGCTGGGCGGGTGGTGCT 
R, CGCGCCACGGCTTGCGGCGCGAGGT 
p, CTGATCATGGGCCTGGGCGCCCAG 
R, GGACCCGTGAGCAGCGCCAGCAGC 
p, GACCTTCACCGCGGCCGACGGTGTC 
R, TGCGTGCAACGCCCTCTTCAGCGCC 
p, GGGATCGAGGCCGTGCGCCAGCGGT 
R, GCACAACCCGTAGCGCCACCAGCCC 
p, CGCACGGTCGAGGACACCAGCACC 
R, ACCCGGTAGGCGCCCAGGTTCGTC 
p, GCCAGACGGGCCGTGGGGGATATG 
R, CCCACCTGGATCAGCGTCGGTGGC 
p, CCCGTGACCAGCTCCCGCGACAAG 
R, GCGGAGCGCTGGCGGTGTATCTCG 
p, TGGGTGACCGGTGAGGCGTCGAGG 
R, AGTGCGGGCGGTCTCCTGGCTGGT 
p, GCATGTGGACACGGCGTGTGCAGG 
R, AACCGGCACAGCGCGTCATGGGTG 
p, ACCCCTGGACCGGTGCTCGAAGCG 
R, GGATCAGGGAGTCGTGGCGGCCGT 
p, GGACCAGCTCCATGTGCTCGCGGC 
R, GGGCTCGTGCGCGTCGGAGTTCAC 
p, CCGGCGAACAGTCAGAGGCTGCCC 
R, GGGCGTTGGGGAGCTCAGCGTAGG 
p, CCACTGTTCGCTTCCCGCCGGCTG 
R, TCGTCGCCCGCGGTCTGCATGACG 
p, CGCACCGGGCGAGCGCGCTCATCAG 
R, CCTCGGCGAGCCGATCGGGCTGCTC 
p, ACGGCCACCGGCATCGTTGAAGGC 
R, CGCTGGGCTTTCCGAGATCGCCCTGG 
p, GTGTTGCCGGCGGACGGCACTCGA 
R, GACGCAACGAGCGGATCGCCTCGG 
p, CCCATCGCCGCACCCGATCTGCTGG 
R, GCGCGGTCCCAGTCGACTGCGGATC 
p, ATCGCCGTCGTCACCCCACGACAG 
R, CCGCATCGCCAAGATATGCCCGCC 
p, TTTGTCACCACACGGCCCGATTCG 
R, GCGCGGTTGGCTAATTCGGTGAGC 
p, AGCCGCTGCCGAGGACGAGGTGTC 
R, GGTCCCGGCAGTGCCTCCTTCCTG 
p, CCGAGTGTCCGGGAGTGGCGTGAC 
R, AGCCTCGACCTGCGGGTAGTGGCC 
F: Forward, R: Reverse 
10 
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TABLE 2 
PCR primers used for lipY 
disruption in M. tuberculosis H37Rv 
Primer pairs to amplify 5' and 3'-flanks of lipY 
5'-flank A 
B 
5'-GCTTAAGATGCCGTAGGACCCG-3' 
5'-GGTCTAGAGACATCACCTCCGGC-3' 
5'-GGAAGCTTACTCGGTATCGCCGC-3' 
5'-GGACTAGTGGTGCAAAGTCCGGG-3' 
3-flank c 
D 
Primer pair from the deleted segment 
L\.-F 5'-GTGCAGGCATTGACAGGCGCGGCC-3' 
L\.-R 5'-CCAGGTCCCCACATCGAGCCACGG-3' 
Primer pairs to amplify 
15 genomic flanks in the mutants 
20 
25 
30 
35 
40 
45 
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5'-flank E 
Hl 
3'-flank H2 
F 
5'-GTGACCGGGAGATCCGAGCAGAGG-3' 
5'-TGAGGCGATGGTGGTGTCGATGCT-3' 
5'-GGAACTGGCGCAGTTCCTCTGGGG-3' 
5'-CCAAGGGCTGGGGTGCACAACTCC-3' 
TABLE3 
Long-Chain TG Hydro lase activity of expressed lip genes 
Effector 
None 
NaCl 
KC! 
MgC12 
MnC12 
Gene 
Product 
LIPY 
LIPK 
LIPL 
LIPC 
LIPX 
LIPG 
LIPE 
LIPQ 
LIPR 
LIPP 
LIPT 
LIPW 
LIPD 
LIPJ 
LIPZ 
LIPS 
LIPM 
LIPO 
LIPF 
LIPH 
LIP! 
LIPN 
LIPU 
LIPV 
TG hydrolase 
activity 
(nrnol/mg/min) 
TABLE4 
48.6 
5.6 
3.4 
3.3 
0.6 
0.4 
0.14 
0.11 
0.11 
0.06 
0.06 
0.05 
0.05 
0.04 
0.03 
0.03 
0.02 
0.005 
0 
0 
0 
0 
0 
0 
Effect of salts on LIPY activity 
Concentration 
200 mM 
50 mM 
100 mM 
50 mM 
100 mM 
10 mM 
50 mM 
50 mM 
100 mM 
Activity 
(nrnol/mg/min) 
Mean± SD 
643.3 ± 65.0 
681.3 ± 87.2 
675.2 ± 103.5 
686.8 ± 68.8 
306.3 ± 111.1 
219.9 ± 34.3 
358.7 ± 4.2 
5.1 ± 2.5 
354.3 ± 136.5 
93.8 ± 7.8 
US 8,039,605 B2 
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TABLE 4-continued TABLE 5-continued 
Effect of salts on LIPY activity Lipase/Esterase-like Proteins in M tuberculosis 
Effector 
CoC12 
CaC12 
Concentration 
10 mM 
50 mM 
50 mM 
100 mM 
200 mM 
50 mM 
100 mM 
50 mM 
100 mM 
Activity 
(nmol/mg/min) 
Mean± SD 
424.8 ± 21.2 
22.9 ± 9.9 
405.1 ±-
433.8 ±-
103.7 ± 29.8 
692.6 ± 57.0 
749.0 ± 73.3 
681.7 ± 80.3 
729.3 ± 96.5 
Purified LIPY protein was incubated for 15 min at room temperature with indicated con-
centrations of salts and then assayed radiometrically for triolein hydrolase activity as 
described in Experimental Procedures. 
TABLES 
Lipase/Esterase-like Proteins in M tuberculosis 
Theoretical Conserved 
MW pl Active-site 
Gene Product Identity (%) kDa Residues 
Gene Product 
LIPL (Rv1497) 
LIPD (Rv1923) 
10 LIPH (Rv1399c) 
LIPE (Rv3775) 
LIPU (Rv1076) 
LIPW (Rv0217c) 
LIPO (Rv1426c) 
LIP! (Rv1400c) 
15 LIPQ (Rv2485c) 
LIPN (Rv2970c) 
LIPG (Rv0646c) 
LIPK (Rv2385) 
LIPF (Rv3487c) 
LIPT (Rv2045c) 
LIPZ* (Rv1834) 
20 LIPR (Rv3084) 
LIPC (Rv0220) 
LIPJ (Rv1900c) 
LIPV (Rv3203) 
LIPS (Rv3176c) 
LIPX* (Rvl 169c) 
25 
Identity (%) 
19.5 
19.0 
18.9 
18.8 
18.5 
18.4 
18.3 
18.2 
18.2 
18.1 
17.9 
17.9 
17.8 
17.6 
17.4 
17.1 
16.7 
16.4 
15.8 
15.2 
8.7 
Theoretical Conserved 
MW 
kDa 
45.8 
47.2 
33.9 
45.3 
31.7 
32.2 
46.1 
34.0 
45.2 
40.1 
32.9 
32.9 
29.4 
56.1 
31.6 
32.6 
44.3 
49.7 
23.6 
35.2 
10.8 
pl Active-site 
9.3 
6.7 
Residues 
4.3 GW§LG 
8.6 
6.3 GDSAG 
8.3 GA§AG 
10.5 
4.6 GD§AG 
8.9 
6.4 GD§AG 
9.9 GA§MG 
8.1 
7.7 GDSAG 
8.7 GE§AG 
9.4 
9.9 GDSAG 
10.4 GCSAG 
5.4 
4.5 GH§FG 
6.4 
5.9 
LIPY* (Rv3097c) 
LIPP (Rv2463) 
LIPM (Rv2284) 
100.0 
21.4 
21.0 
45.0 
42.8 
46.7 
4.5 GD§AG 
6.0 
Amino acid identity of lipase genes were compared by pairwise alignment with LIPY, which 
had the highest TG hydrolase activity, using the ALIGN software program at Genestream 
(igh.cnrs.fr/bin/align-guess.cgi). 
<160> NUMBER OF SEQ ID NOS, 81 
<210> SEQ ID NO 1 
<211> LENGTH, 1315 
<212> TYPE, DNA 
9.6 
SEQUENCE LISTING 
<213> ORGANISM: Mycobacterium tuberculosis 
<400> SEQUENCE, 1 
*We identified these genes as putative lipases as described in Experimental Procedures. 
gtggtgtctt atgttgttgc gttgccggag gtgatgtccg ccgcggccac agacgtggct 60 
tcgattggtt cggtggtcgc gacggcgagc cagggtgtcg cgggtgccac cacgacggta 120 
ttagccgctg ccgaggacga ggtgtcagcc gcgatcgcgg ctttgttttc cggccatggt 180 
caggactatc aagctcttag cgcacagctt gcggtgtttc atgagcggtt tgtgcaggca 240 
ttgacaggcg cggccaaggg gtatgccgcc gccgagctgg ccaacgcttc gctgttgcag 300 
agtgaattcg ccagcggtat cgggaacggt tttgccacga ttcaccagga aattcagcgg 360 
gcccccacgg cgctggccgc cggattcacg caggttccgc ctttcgcggc ggcgcaggca 420 
gggatcttca ccggcacgcc gtcaggggct gccggattcg acatcgcttc gctgtggccg 480 
gtgaaacccc tgctgagttt gtctgcgctc gaaactcact ttgcaatccc aaacaatcca 540 
cttttagcgc tcattgccag cgacataccg ccgctgtcgt ggtttcttgg caactcccca 600 
ccgccgttgc tgaactcgct gctgggacag acggtccagt acaccaccta tgacgggatg 660 
agcgtcgtgc agatcacgcc ggctcatcca accggcgaat acgtggttgc cattcacggc 720 
ggcgcgttta tcctgccgcc gtcaatcttc cactggctca actactcggt gacggcttac 780 
cagaccggcg cgaccgtgca agtgccgatt tacccgttgg tgcaggaagg aggcactgcc 840 
gggacggtag taccggcgat ggccgggctc atctccacgc aaatcgcgca acacggggtc 900 
tccaacgtca gcgtggtcgg ggactccgcg ggcggcaacc tcgcactggc ggccgcccaa 960 
US 8,039,605 B2 
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tacatggtga gccagggcaa cccagtaccg tcgtccatgg tgttgctgtc cccgtggctc 
gatgtgggga cctggcagat cagccaggcg tgggcaggca atcttgcggt caacgacccg 
ctggtcagtc cgctgtatgg gtcgctgaac ggtcttccgc cgacgtatgt ctattcgggc 
tcgcttgatc cgctcgcaca acaagcggtt gtcctcgagc acacagccgt agtccaagga 
gcgccgttca gcttcgtact ggccccctgg caaatccacg actggatact gctcaccccc 
tggggtttgc tgtcctggcc gcagattaac cagcaactcg gtatcgccgc ctgat 
<210> SEQ ID NO 2 
<211> LENGTH, 437 
<212> TYPE, PRT 
<213> ORGANISM: Mycobacterium tuberculosis 
<400> SEQUENCE, 2 
Met Val Ser Tyr Val Val Ala Leu Pro Glu Val Met Ser Ala Ala Ala 
1 5 10 15 
Thr Asp Val Ala Ser Ile Gly Ser Val Val Ala Thr Ala Ser Gln Gly 
20 25 30 
Val Ala Gly Ala Thr Thr Thr Val Leu Ala Ala Ala Glu Asp Glu Val 
35 40 45 
Ser Ala Ala Ile Ala Ala Leu Phe Ser Gly His Gly Gln Asp Tyr Gln 
50 55 60 
Ala Leu Ser Ala Gln Leu Ala Val Phe His Glu Arg Phe Val Gln Ala 
65 70 75 80 
Leu Thr Gly Ala Ala Lys Gly Tyr Ala Ala Ala Glu Leu Ala Asn Ala 
85 90 95 
Ser Leu Leu Gln Ser Glu Phe Ala Ser Gly Ile Gly Asn Gly Phe Ala 
100 105 110 
Thr Ile His Gln Glu Ile Gln Arg Ala Pro Thr Ala Leu Ala Ala Gly 
115 120 125 
Phe Thr Gln Val Pro Pro Phe Ala Ala Ala Gln Ala Gly Ile Phe Thr 
130 135 140 
Gly Thr Pro Ser Gly Ala Ala Gly Phe Asp Ile Ala Ser Leu Trp Pro 
145 150 155 160 
Val Lys Pro Leu Leu Ser Leu Ser Ala Leu Glu Thr His Phe Ala Ile 
165 170 175 
Pro Asn Asn Pro Leu Leu Ala Leu Ile Ala Ser Asp Ile Pro Pro Leu 
180 185 190 
Ser Trp Phe Leu Gly Asn Ser Pro Pro Pro Leu Leu Asn Ser Leu Leu 
195 200 205 
Gly Gln Thr Val Gln Tyr Thr Thr Tyr Asp Gly Met Ser Val Val Gln 
210 215 220 
Ile Thr Pro Ala His Pro Thr Gly Glu Tyr Val Val Ala Ile His Gly 
225 230 235 240 
Gly Ala Phe Ile Leu Pro Pro Ser Ile Phe His Trp Leu Asn Tyr Ser 
245 250 255 
Val Thr Ala Tyr Gln Thr Gly Ala Thr Val Gln Val Pro Ile Tyr Pro 
260 265 270 
Leu Val Gln Glu Gly Gly Thr Ala Gly Thr Val Val Pro Ala Met Ala 
275 280 285 
Gly Leu Ile Ser Thr Gln Ile Ala Gln His Gly Val Ser Asn Val Ser 
290 295 300 
Val Val Gly Asp Ser Ala Gly Gly Asn Leu Ala Leu Ala Ala Ala Gln 
305 310 315 320 
30 
1020 
1080 
1140 
1200 
1260 
1315 
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Tyr Met Val Ser Gln Gly Asn Pro Val Pro Ser Ser Met Val Leu Leu 
325 330 335 
Ser Pro Trp Leu Asp Val Gly Thr Trp Gln Ile Ser Gln Ala Trp Ala 
340 345 350 
Gly Asn Leu Ala Val Asn Asp Pro Leu Val Ser Pro Leu Tyr Gly Ser 
355 360 365 
Leu Asn Gly Leu Pro Pro Thr Tyr Val Tyr Ser Gly Ser Leu Asp Pro 
370 375 380 
Leu Ala Gln Gln Ala Val Val Leu Glu His Thr Ala Val Val Gln Gly 
385 390 395 400 
Ala Pro Phe Ser Phe Val Leu Ala Pro Trp Gln Ile His Asp Trp Ile 
405 410 415 
Leu Leu Thr Pro Trp Gly Leu Leu Ser Trp Pro Gln Ile Asn Gln Gln 
420 
Leu Gly Ile Ala Ala 
435 
<210> SEQ ID NO 3 
<211> LENGTH, 24 
<212> TYPE, DNA 
425 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
430 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
ggtaagcacc tcaagccgct cggc 
<210> SEQ ID NO 4 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 4 
gcgctgaacc actacccgct ccag 
<210> SEQ ID NO 5 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 5 
ggtgttcagc gggcgagcga gttc 
<210> SEQ ID NO 6 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 
ggcgcaacca ccgtcactcc tcac 
<210> SEQ ID NO 7 
<211> LENGTH, 24 
32 
24 
24 
24 
24 
33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 7 
ctagacgccg tcacggcaac cggc 
<210> SEQ ID NO 8 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 8 
actgggcgcg accagcggca catc 
<210> SEQ ID NO 9 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 9 
cgacggcgct gggcgggtgg tgct 
<210> SEQ ID NO 10 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 10 
cgcgccacgg cttgcggcgc gaggt 
<210> SEQ ID NO 11 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 11 
ctgatcatgg gcctgggcgc ccag 
<210> SEQ ID NO 12 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 12 
ggacccgtga gcagcgccag cage 
<210> SEQ ID NO 13 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
34 
24 
24 
24 
25 
24 
24 
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<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 13 
gaccttcacc gcggccgacg gtgtc 
<210> SEQ ID NO 14 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 14 
tgcgtgcaac gccctcttca gcgcc 
<210> SEQ ID NO 15 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 15 
gggatcgagg ccgtgcgcca gcggt 
<210> SEQ ID NO 16 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 16 
gcacaacccg tagcgccacc agccc 
<210> SEQ ID NO 17 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 17 
cgcacggtcg aggacaccag cacc 
<210> SEQ ID NO 18 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 18 
acccggtagg cgcccaggtt cgtc 
<210> SEQ ID NO 19 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
36 
25 
25 
25 
25 
24 
24 
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primer 
<400> SEQUENCE, 19 
gccagacggg ccgtggggga tatg 24 
<210> SEQ ID NO 20 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 20 
cccacctgga tcagcgtcgg tggc 24 
<210> SEQ ID NO 21 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 21 
cccgtgacca gctcccgcga caag 24 
<210> SEQ ID NO 22 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 22 
gcggagcgct ggcggtgtat ct cg 24 
<210> SEQ ID NO 23 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 23 
tgggtgaccg gtgaggcgtc gagg 24 
<210> SEQ ID NO 24 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 24 
agtgcgggcg gtctcctggc tggt 24 
<210> SEQ ID NO 25 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
US 8,039,605 B2 
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-continued 
<400> SEQUENCE, 25 
gcatgtggac acggcgtgtg cagg 24 
<210> SEQ ID NO 26 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 26 
aaccggcaca gcgcgtcatg ggtg 24 
<210> SEQ ID NO 27 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 27 
acccctggac cggtgctcga agcg 24 
<210> SEQ ID NO 28 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 28 
ggatcaggga gtcgtggcgg ccgt 24 
<210> SEQ ID NO 29 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 29 
ggaccagctc catgtgctcg cggc 24 
<210> SEQ ID NO 30 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 30 
gggctcgtgc gcgtcggagt tcac 24 
<210> SEQ ID NO 31 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 31 
US 8,039,605 B2 
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ccggcgaaca gtcagaggct gccc 24 
<210> SEQ ID NO 32 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 32 
gggcgttggg gagctcagcg tagg 24 
<210> SEQ ID NO 33 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 33 
ccactgttcg cttcccgccg gctg 24 
<210> SEQ ID NO 34 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 34 
tcgtcgcccg cggtctgcat gacg 24 
<210> SEQ ID NO 35 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 35 
cgcaccgggc gagcgcgctc atcag 25 
<210> SEQ ID NO 36 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 36 
cctcggcgag ccgatcgggc tgctc 25 
<210> SEQ ID NO 37 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence: Synthetic 
primer 
<400> SEQUENCE, 37 
acggccaccg gcatcgttga aggc 24 
<210> SEQ ID NO 38 
<211> LENGTH, 26 
<212> TYPE, DNA 
43 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 38 
cgctgggctt tccgagatcg ccctgg 
<210> SEQ ID NO 39 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 39 
gtgttgccgg cggacggcac tcga 
<210> SEQ ID NO 40 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 40 
gacgcaacga gcggatcgcc tcgg 
<210> SEQ ID NO 41 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 41 
cccatcgccg cacccgatct gctgg 
<210> SEQ ID NO 42 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 42 
gcgcggtccc agtcgactgc ggatc 
<210> SEQ ID NO 43 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 43 
atcgccgtcg tcaccccacg acag 
<210> SEQ ID NO 44 
44 
26 
24 
24 
25 
25 
24 
<211> LENGTH, 24 
<212> TYPE, DNA 
45 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 8,039,605 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 44 
ccgcatcgcc aagatatgcc cgcc 
<210> SEQ ID NO 45 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 45 
tttgtcacca cacggcccga ttcg 
<210> SEQ ID NO 46 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 46 
gcgcggttgg ctaattcggt gage 
<210> SEQ ID NO 47 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 47 
agccgctgcc gaggacgagg tgtc 
<210> SEQ ID NO 48 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 48 
cgtcccggca gtgcctcctt cctg 
<210> SEQ ID NO 49 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 49 
ccgagtgtcc gggagtggcg tgac 
<210> SEQ ID NO 50 
<211> LENGTH, 24 
<212> TYPE, DNA 
46 
24 
24 
24 
24 
24 
24 
47 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 8,039,605 B2 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 50 
agcctcgacc tgcgggtagt ggcc 
<210> SEQ ID NO 51 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 51 
gcttaagatg ccgtaggacc cg 
<210> SEQ ID NO 52 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 52 
ggtctagaga catcacctcc ggc 
<210> SEQ ID NO 53 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 53 
ggaagcttac tcggtatcgc cgc 
<210> SEQ ID NO 54 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 54 
ggactagtgg tgcaaagtcc ggg 
<210> SEQ ID NO 55 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 55 
gtgcaggcat tgacaggcgc ggcc 
<210> SEQ ID NO 56 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
48 
24 
22 
23 
23 
23 
24 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 56 
ccaggtcccc acatcgagcc acgg 
<210> SEQ ID NO 57 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 57 
gtgaccggga gatccgagca gagg 
<210> SEQ ID NO 58 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 58 
tgaggcgatg gtggtgtcga tgct 
<210> SEQ ID NO 59 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 59 
ggaactggcg cagttcctct gggg 
<210> SEQ ID NO 60 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 60 
ccaagggctg gggtgcacaa ctcc 
<210> SEQ ID NO 61 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 61 
Gly Asp Ser Ala Gly 
1 5 
<210> SEQ ID NO 62 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
50 
24 
24 
24 
24 
24 
peptide 
<400> SEQUENCE, 62 
Gly Trp Ser Leu Gly 
1 5 
<210> SEQ ID NO 63 
<211> LENGTH, 5 
<212> TYPE, PRT 
51 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 63 
Gly Ala Ser Ala Gly 
1 5 
<210> SEQ ID NO 64 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 64 
Gly Ala Ser Met Gly 
1 5 
<210> SEQ ID NO 65 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 65 
Gly Glu Ser Ala Gly 
1 5 
<210> SEQ ID NO 66 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 66 
Gly Cys Ser Ala Gly 
1 5 
<210> SEQ ID NO 67 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 67 
Gly His Ser Phe Gly 
1 5 
<210> SEQ ID NO 68 
<211> LENGTH, 4 
52 
US 8,039,605 B2 
53 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 68 
His Gly Gly Gly 
1 
<210> SEQ ID NO 69 
<211> LENGTH, 178 
<212> TYPE, PRT 
<213> ORGANISM: Mycobacterium tuberculosis 
<400> SEQUENCE, 69 
Glu Tyr Val Val Ala Ile His Gly Gly Ala Phe Ile Leu Pro Pro Ser 
1 5 10 15 
Ile Phe His Trp Leu Asn Tyr Ser Val Thr Ala Tyr Gln Thr Gly Ala 
20 25 30 
Thr Val Gln Val Pro Ile Tyr Pro Leu Val Gln Glu Gly Gly Thr Ala 
35 40 45 
Gly Thr Val Val Pro Ala Met Ala Gly Leu Ser Asn Val Ser Val Val 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Leu Ala Leu Ala Ala Ala Gln Tyr Met 
65 70 75 80 
Val Ser Gln Gly Asn Pro Val Pro Ser Ser Met Val Leu Leu Ser Pro 
85 90 95 
Trp Leu Asp Val Gly Thr Trp Gln Ile Ser Gln Ala Trp Ala Gly Asn 
100 105 110 
Leu Ala Val Asn Leu Pro Pro Thr Tyr Val Tyr Ser Gly Ser Leu Asp 
115 120 125 
Pro Leu Ala Gln Gln Ala Val Val Leu Glu His Thr Ala Val Val Gln 
130 135 140 
Gly Ala Pro Phe Ser Phe Val Leu Ala Pro Trp Gln Ile His Asp Trp 
145 150 155 160 
Ile Leu Leu Thr Pro Trp Gly Leu Leu Ser Trp Pro Gln Ile Asn Gln 
165 170 175 
Gln Leu 
<210> SEQ ID NO 70 
<211> LENGTH, 181 
<212> TYPE, PRT 
<213> ORGANISM, Archaeoglobus fulgidus 
<400> SEQUENCE, 70 
Pro Val Leu Val Tyr Tyr His Gly Gly Gly Phe Val Ile Cys Ser Ile 
1 5 10 15 
Glu Ser His Asp Ala Leu Cys Arg Arg Ile Ala Arg Leu Ser Asn Ser 
20 25 30 
Thr Val Val Ser Val Asp Tyr Arg Leu Ala Pro Glu His Lys Phe Pro 
35 40 45 
Ala Ala Val Tyr Asp Cys Tyr Asp Ala Thr Ser Lys Ile Phe Val Gly 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Leu Ala Ala Ala Val Ser Ile Met Ala 
65 70 75 80 
Arg Asp Ser Gly Glu Asp Phe Ile Lys His Gln Ile Leu Ile Tyr Pro 
85 90 95 
54 
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-continued 
Val Val Asn Phe Val Ala Pro Thr Pro Ser Leu Leu Glu Phe Gly Glu 
100 105 110 
Gly Leu Trp Ile Leu Pro Pro Ala Leu Ile Ile Thr Ala Glu Tyr Asp 
115 120 125 
Pro Leu Arg Asp Glu Gly Glu Val Phe Gly Gln Met Leu Arg Arg Ala 
130 135 140 
Gly Val Glu Ala Ser Ile Val Arg Tyr Arg Gly Val Leu His Gly Phe 
145 150 155 160 
Ile Asn Tyr Tyr Pro Val Leu Lys Ala Ala Arg Asp Ala Ile Asn Gln 
165 170 175 
Ile Ala Ala Leu Leu 
180 
<210> SEQ ID NO 71 
<211> LENGTH, 180 
<212> TYPE, PRT 
<213> ORGANISM: Acinetobacter esterase 
<400> SEQUENCE, 71 
Pro Leu Ile Val Phe Tyr His Gly Gly Gly 
1 5 10 
Asp Ser His Asp Glu Phe Cys Arg Leu Met 
20 25 
Phe Val Val Gly Gly 
15 
Ala Val His Ala His 
30 
Leu 
Ala 
Gln Val Leu Ser Val Glu Tyr Pro Leu Ala Pro Glu Ala Ser Pro Gln 
35 40 45 
Gln Ile Ile Gln Val Cys Glu Asp Ala Leu Asn Arg Ile Ala Val Ala 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Ile Ala Ala Val Val Ala Gln Arg Ser 
65 70 75 80 
Ala Gln Ser Ala Tyr Ala Pro Asn Ala Gln Phe Leu Ile Tyr Pro Ala 
85 90 95 
Leu Asp Phe Lys Ser Arg His Pro Ser Phe Phe Ala Tyr Lys Asp Gly 
100 105 110 
Leu Val Leu Leu Ala Pro Ala Phe Val Val Thr Ala Gly His Asp Val 
115 120 125 
Leu His Asp Glu Ala Glu Ile Tyr Ala His Lys Leu Arg Gln Asn Gln 
130 135 140 
Val Thr Val Lys Tyr Val Glu Tyr Leu Asp Gln Thr His Gly Phe Ile 
145 150 155 160 
Ser Met Thr Phe Val Ser Arg Arg Ala Lys Lys Ile Ser Ile Glu Leu 
Cys Lys Asn Phe 
180 
165 170 175 
<210> SEQ ID NO 72 
<211> LENGTH, 183 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 72 
Ser Leu Ile Val His Phe His Gly Gly Gly Phe Val Ala Gln Thr Ser 
1 5 10 15 
Arg Ser His Glu Pro Tyr Leu Lys Ser Trp Ala Gln Glu Leu Gly Ala 
20 25 30 
Pro Ile Ile Ser Ile Asp Tyr Ser Leu Ala Pro Glu Ala Pro Phe Pro 
35 40 45 
Arg Ala Leu Glu Glu Cys Phe Phe Ala Tyr Glu Arg Ile Cys Leu Ala 
56 
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-continued 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Leu Cys Phe Thr Val Ala Leu Arg Ala 
65 70 75 80 
Ala Ala Tyr Gly Val Arg Val Pro Asp Gly Ile Met Ala Ala Tyr Pro 
85 90 95 
Ala Thr Met Leu Gln Pro Ala Ala Ser Pro Ser Arg Leu Leu Ser Leu 
100 105 110 
Met Asp Pro Leu Leu Pro Pro Val His Ile Val Ala Cys Ala Leu Asp 
115 120 125 
Pro Met Leu Asp Asp Ser Val Met Leu Ala Arg Arg Leu Arg Asn Leu 
130 135 140 
Gly Gln Pro Val Thr Leu Arg Val Val Glu Asp Leu Pro His Gly Phe 
145 150 155 160 
Leu Thr Leu Ala Ala Leu Cys Arg Glu Thr Arg Gln Ala Ala Glu Leu 
165 170 175 
Cys Val Glu Arg Ile Arg Leu 
180 
<210> SEQ ID NO 73 
<211> LENGTH, 183 
<212> TYPE, PRT 
<213> ORGANISM, Pseudomonas sp. 
<400> SEQUENCE, 73 
Pro Leu Leu Val Phe Phe His Gly Gly Gly Phe Val Met Gly Asn Leu 
1 5 10 15 
Asp Thr His Asp Asn Leu Cys Arg Ser Leu Ala Ser Gln Thr Glu Ala 
20 25 30 
Val Val Val Ser Val Ala Tyr Arg Leu Ala Pro Glu Asn His Phe Pro 
35 40 45 
Ala Ala Pro Leu Asp Cys Tyr Ala Ala Thr Arg Arg Leu Ala Leu Ala 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Leu Ala Leu Ala Val Ser Arg Leu Ala 
65 70 75 80 
Ala Gln Arg Gln Gly Pro Lys Ile Ser Tyr Gln Cys Leu Phe Tyr Pro 
85 90 95 
Val Thr Asp Ala Arg Cys Asp Ser Gln Ser Tyr Glu Glu Phe Ala Glu 
100 105 110 
Gly Tyr Phe Leu Leu Pro Pro Thr Thr Leu Ile Thr Ala Glu Phe Asp 
115 120 125 
Pro Leu Arg Asp Glu Gly Glu Ala Phe Ala Leu Arg Leu Gln Gln Ala 
130 135 
Gly Val Ser Val Arg Val Gln Arg Cys Glu 
145 150 
Ile Ser Met Ala Pro Phe Val Glu Arg 
165 
Ala Ala Ala Asp Leu Arg Arg 
180 
<210> SEQ ID NO 74 
<211> LENGTH, 185 
<212> TYPE, PRT 
<213> ORGANISM, Bacillus subtilis 
<400> SEQUENCE, 74 
Ala 
170 
140 
Gly Met Ile His Gly Phe 
155 160 
Ala His Ala Leu Ser Asp 
175 
Pro Gly Leu Val Tyr Thr His Gly Gly Gly Met Thr Ile Leu Thr Thr 
1 5 10 15 
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-continued 
Asp Asn Arg Val His Arg Arg Trp Cys Thr Asp Leu Ala Ala Ala Gly 
20 25 30 
Ser Val Val Val Met Val Asp Phe Arg Asn Ala Trp Thr Ala Glu Gly 
35 40 45 
His His Pro Phe Pro Ser Gly Val Glu Asp Cys Leu Ser Gly Val Val 
50 55 60 
Val Gln Gly Glu Ser Gly Gly Gly Asn Leu Ala Ile Ala Thr Thr Leu 
65 70 75 80 
Leu Ala Lys Arg Arg Gly Arg Leu Asp Ala Ile Asp Gly Val Tyr Ala 
85 90 95 
Ser Ile Pro Tyr Ile Ser Gly Gly Tyr Ala Trp Asp His Glu Arg Arg 
100 105 110 
Leu Thr Glu Leu Pro Ser Leu Pro Pro Phe Val Val Ala Val Asn Glu 
115 120 125 
Leu Asp Pro Leu Arg Asp Glu Gly Ile Ala Phe Ala Arg Arg Leu Ala 
130 135 140 
Arg Ala Gly Val Asp Val Ala Ala Arg Val Asn Ile Gly Leu Val His 
145 150 155 160 
Gly Ala Asp Val Ile Phe Arg His Trp Leu Pro Ala Ala Leu Glu Ser 
165 170 175 
Thr Val Arg Asp Val Ala Gly Phe Ala 
180 185 
<210> SEQ ID NO 75 
<211> LENGTH, 181 
<212> TYPE, PRT 
<213> ORGANISM: Mycobacterium tuberculosis 
<400> SEQUENCE, 75 
Arg Ala Val Leu Tyr Leu His Gly Gly Ala Phe Leu Thr Cys Gly Ala 
1 5 10 15 
Asn Ser His Gly Arg Leu Val Glu Leu Leu Ser Lys Phe Ala Asp Ser 
20 25 30 
Pro Val Leu Val Val Asp Tyr Arg Leu Ile Pro Lys His Ser Ile Gly 
35 40 45 
Met Ala Leu Asp Asp Cys His Asp Gly Tyr Glu Gln Ile Val Leu Ala 
50 55 60 
Gly Asp Ser Ala Gly Gly Tyr Leu Ala Leu Ala Leu Ala Gln Arg Leu 
65 70 75 80 
Gln Glu Val Gly Glu Glu Pro Ala Ala Leu Val Ala Ile Ser Pro Leu 
85 90 95 
Leu Gln Leu Ala Lys Glu His Lys Gln Ala His Pro Asn Ile Lys Thr 
100 105 110 
Asp Ala Met Phe Leu Pro Arg Thr Leu Ile His Val Ser Gly Ser Glu 
115 120 125 
Val Leu Leu His Asp Ala Gln Leu Ala Ala Ala Lys Leu Ala Ala Ala 
130 135 140 
Gly Val Pro Ala Glu Val Arg Val Trp Pro Gly Gln Val His Asp Phe 
145 150 155 160 
Gln Val Ala Ala Ser Met Leu Pro Glu Ala Ile Arg Ser Leu Arg Gln 
165 170 175 
Ile Gly Glu Tyr Ile 
180 
<210> SEQ ID NO 76 
60 
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<211> LENGTH, 178 
<212> TYPE, PRT 
61 
<213> ORGANISM: Mycobacterium tuberculosis 
<400> SEQUENCE, 76 
-continued 
Glu Tyr Val Val Ala Ile His Gly Gly Ala Phe Ile Leu Pro Pro Ser 
1 5 10 15 
Ile Phe His Trp Leu Asn Tyr Ser Val Thr Ala Tyr Gln Thr Gly Ala 
20 25 30 
Thr Val Gln Val Pro Ile Tyr Pro Leu Val Gln Glu Gly Gly Thr Ala 
35 40 45 
Gly Thr Val Val Pro Ala Met Ala Gly Leu Ser Asn Val Ser Val Val 
50 55 60 
Gly Asp Ser Ala Gly Gly Asn Leu Ala Leu Ala Ala Ala Gln Tyr Met 
65 70 75 80 
Val Ser Gln Gly Asn Pro Val Pro Ser Ser Met Val Leu Leu Ser Pro 
85 90 95 
Trp Leu Asp Val Gly Thr Trp Gln Ile Ser Gln Ala Trp Ala Gly Asn 
100 105 110 
Leu Ala Val Asn Leu Pro Pro Thr Tyr Val Tyr Ser Gly Ser Leu Asp 
115 120 125 
Pro Leu Ala Gln Gln Ala Val Val Leu Glu His Thr Ala Val Val Gln 
130 135 140 
Gly Ala Pro Phe Ser Phe Val Leu Ala Pro Trp Gln Ile His Asp Trp 
145 150 155 160 
Ile Leu Leu Thr Pro Trp Gly Leu Leu Ser Trp Leu Gln Ile Asn Gln 
165 170 175 
Gln Leu 
<210> SEQ ID NO 77 
<211> LENGTH, 181 
<212> TYPE, PRT 
<213> ORGANISM: Ralstonia solanacearum 
<400> SEQUENCE, 77 
Pro Val Val Phe Tyr Leu His Gly Gly Gly 
1 5 10 
Arg Thr His Arg Ser Ile Thr Ile Gly Leu 
20 25 
Tyr Phe Phe Cys Ser 
15 
Ala Val His Ala Arg 
30 
Pro 
Ala 
Arg Val Phe Ala Leu Asp Tyr Arg Leu Ala Pro Glu His Pro Phe Pro 
35 40 45 
Ala Ala Val Leu Asp Ala Leu Ala Gly Tyr Ser Arg Ile Val Val Ala 
50 55 60 
Gly Asp Ser Ala Gly Gly Gly Leu Ser Leu Ala Leu Leu Val Ala Leu 
65 70 75 80 
Arg Asp Ala Gly Asp Pro Leu Pro Ala Gly Ala Ile Leu Tyr Ser Pro 
85 90 95 
Trp Thr Asp Leu Ala Ala Thr Gly Ala Ser Leu Val Glu Asn Asp Ala 
100 105 110 
Ser Asp Val Met Leu Pro Pro Leu His Cys Tyr Val Ser Thr Ser Glu 
115 120 125 
Val Leu Arg Asp Asp Thr Leu Arg Met Ala Glu Arg Ala Arg Ala Ala 
130 135 140 
Gly Val Ser Val Ser Val Glu Leu Gly Arg Arg Leu Pro His Val Trp 
145 150 155 160 
Pro Ile Phe Tyr Pro Phe Leu Pro Glu Ala Arg Lys Ala Leu Arg Gln 
62 
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Ser Gly Asp Ala Val 
180 
<210> SEQ ID NO 78 
<211> LENGTH, 179 
<212> TYPE, PRT 
63 
170 
<213> ORGANISM, Staphylococcus aureus 
<400> SEQUENCE, 78 
-continued 
175 
Arg Val Val Leu Tyr Ala His Gly Gly Ala Trp Phe Gln Asp Pro Leu 
1 5 10 15 
Lys Ile His Phe Glu Phe Ile Asp Glu Leu Ala Glu Thr Leu Asn Ala 
20 25 30 
Lys Val Ile Met Pro Val Tyr Pro Lys Ile Pro His Gln Asp Tyr Gln 
35 40 45 
Ala Thr Tyr Val Leu Phe Glu Lys Leu Tyr Lys Gln Ile Val Val Met 
50 55 60 
Gly Asp Ser Ala Gly Gly Gln Ile Ala Leu Ser Phe Ala Gln Leu Leu 
65 70 75 80 
Lys Glu Lys His Ile Val Gln Pro Gly His Ile Val Leu Ile Ser Pro 
85 90 95 
Val Leu Asp Ala Thr Met Gln His Pro Glu Ile Pro Asp Tyr Leu Lys 
100 105 110 
Lys Asp Pro Met Leu Gly Arg Ile Thr Leu Thr Val Gly Thr Lys Glu 
115 120 125 
Val Leu Tyr Pro Asp Ala Leu Asn Leu Ser Gln Leu Leu Ser Ala Lys 
130 135 140 
Gly Ile Glu His Asp Phe Ile Pro Gly Tyr Tyr Gln Phe His Ile Tyr 
145 150 155 160 
Pro Val Phe Pro Ile Pro Glu Arg Arg Arg Phe Leu Tyr Gln Val Lys 
165 170 175 
Asn Ile Ile 
<210> SEQ ID NO 79 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6x His tag 
<400> SEQUENCE, 79 
His His His His His His 
1 5 
<210> SEQ ID NO 80 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Portion of 
TG hydrolase 
<400> SEQUENCE, 80 
Gly Asp Ser Asp Gly 
1 5 
<210> SEQ ID NO 81 
<211> LENGTH, 4 
<212> TYPE, PRT 
64 
US 8,039,605 B2 
65 66 
-continued 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Portion of 
TG hydrolase 
<400> SEQUENCE, 41 
His Gly Gly Gly 
1 
What is claimed is: 
1. A polynucleotide comprising a nucleic acid sequence 
encoding SEQ ID NO. 2, or a polypeptide having at least 90 
percent identity to SEQ ID NO. 2, wherein said polynucle-
otide is in an expression vector. 
2. The polynucleotide sequence of claim 1, wherein said 
nucleic acid sequence comprises a sequence that encodes 
GDSAG (SEQ ID NO. 61). 
3. The polynucleotide sequence of claim 1, wherein said 
nucleic acid sequence comprises a sequence that encodes 
HGGG (SEQ ID NO. 68). 
5. An agent which regulates the activity of a M. tuberculo-
sis TG hydrolase (MTTGH) polypeptide, wherein said agent 
is an RNA molecule, an antisense oligonucleotide, or a 
15 ribozyme that targets a nucleic acid sequence that encodes 
SEQ ID NO. 2. 
6. An isolated polypeptide d-comprising SEQ ID NO. 2. 
7. A recombinant cell host containing a purified MTTGH 
polynucleotide or a recombinant vector comprising a 
20 MTTGH polynucleotide, wherein said MTTGH polynucle-
otide comprises a nucleic acid sequence that encodes SEQ ID 
NO. 2, or a polypeptide having at least 90 percent identity 
therewith. 4. The polynucleotide sequence of claim 1, wherein said 
nucleic acid sequence comprises a sequence that encodes 
GDSAG (SEQ ID NO. 61) and a sequence that encodes 25 
HGGG (SEQ ID NO. 68). 
* * * * * 
